Novel Ecdysone Receptor-Based Inducible Gene Expression System

ABSTRACT

This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic plants and animals.

This application claims priority to co-pending U.S. provisionalapplication Ser. No. 60/191,355, filed Mar. 22, 2000 and to co-pendingU.S. provisional application Ser. No. 60/269,799, filed Feb. 20, 2001.

FIELD OF THE INVENTION

This invention relates to the field of biotechnology or geneticengineering. Specifically, this invention relates to the field of geneexpression. More specifically, this invention relates to a novelecdysone receptor-based inducible gene expression system and methods ofmodulating the expression of a gene within a host cell using thisinducible gene expression system.

BACKGROUND OF THE INVENTION

In the field of genetic engineering, precise control of gene expressionis a valuable tool for studying, manipulating, and controllingdevelopment and other physiological processes. Gene expression is acomplex biological process involving a number of specificprotein-protein interactions. In order for gene expression to betriggered, such that it produces the RNA necessary as the first step inprotein synthesis, a transcriptional activator must be brought intoproximity of a promoter that controls gene transcription. Typically, thetranscriptional activator itself is associated With a protein that hasat least one DNA binding domain that binds to DNA binding sites presentin the promoter regions of genes. Thus, for gene expression to occur, aprotein comprising a DNA binding domain and a transactivation domainlocated at an appropriate distance from the DNA binding domain must bebrought into the correct position in the promoter region of the gene.

The traditional transgenic approach utilizes a cell-type specificpromoter to drive the expression of a designed transgene. A DNAconstruct containing the transgene is first incorporated into a hostgenome. When triggered by a transcriptional activator, expression of thetransgene occurs in a given cell type.

Another means to regulate expression of foreign genes in cells isthrough inducible promoters. Examples of the use of such induciblepromoters include the PR1-a promoter, prokaryotic repressor-operatorsystems, immunosuppressive-immunophilin systems, and higher eukaryotictranscription activation systems such as steroid hormone receptorsystems and are described below.

The PR1-a promoter from tobacco is induced during the systemic acquiredresistance response following pathogen attack. The use of PR1-a may belimited because it often responds to endogenous materials and externalfactors such as pathogens, UV-B radiation, and pollutants. Generegulation systems based on promoters induced by heat shock, interferonand heavy metals have been described (Wurn et al., 1986, Proc. Natl.Acad. Sci. USA 83:5414-5418; Arnheiter et al., 1990 Cell 62:51-61;Filmus et al., 1992 Nucleic Acids Research 20:27550-27560). However,these systems have limitations due to their effect on expression ofnon-target genes. These systems are also leaky.

Prokaryotic repressor-operator systems utilize bacterial repressorproteins and the unique operator DNA sequences to which they bind. Boththe tetracycline (“Tet”) and lactose (“Lac”) repressor-operator systemsfrom the bacterium Escherichia coli have been used in plants and animalsto control gene expression. In the Tet system, tetracycline binds to theTetR repressor protein, resulting in a conformational change whichreleases the repressor protein from the operator which as a resultallows transcription to occur. In the Lac system, a lac operon isactivated in response to the presence of lactose, or synthetic analogssuch as isopropyl-b-D-thiogalactoside. Unfortunately, the use of suchsystems is restricted by unstable chemistry of the ligands, i.e.tetracycline and lactose, their toxicity, their natural presence, or therelatively high levels required for induction or repression. For similarreasons, utility of such systems in animals is limited.

Immunosuppressive molecules such as FK506, rapamycin and cyclosporine Acan bind to immunophilins FKBP12, cyclophilin, etc. Using thisinformation, a general strategy has been devised to bring together anytwo proteins simply by placing FK506 on each of the two proteins or byplacing FK506 on one and cyclosporine A on another one. A synthetichomodimer of FK506 (FK1012) or a compound resulted from fusion ofFK506-cyclosporine (FKCsA) can then be used to induce dimerization ofthese molecules (Spencer et al., 1993, Science 262:1019-24; Belshaw etal., 1996 Proc Natl Acad Sci USA 93:4604-7). Gal4 DNA binding domainfused to FKBP12 and VP16 activator domain fused to cyclophilin, andFKCsA compound were used to show heterodimerization and activation of areporter gene under the control of a promoter containing Gal4 bindingsites. Unfortunately, this system includes immunosuppressants that canhave unwanted side effects and therefore, limits its use for variousmammalian gene switch applications.

Higher eukaryotic transcription activation systems such as steroidhormone receptor systems have also been employed. Steroid hormonereceptors are members of the nuclear receptor superfamily and are foundin vertebrate and invertebrate cells. Unfortunately, use of steroidalcompounds that activate the receptors for the regulation of geneexpression, particularly in plants and mammals, is limited due to theirinvolvement in many other natural biological pathways in such organisms.In order to overcome such difficulties, an alternative system has beendeveloped using insect ecdysone receptors (EcR).

Growth, molting, and development in insects are regulated by theecdysone steroid hormone (molting hormone) and the juvenile hormones(Dhadialla, et al., 1998. Annu. Rev. Entomol. 43: 545-569). Themolecular target for ecdysone in insects consists of at least ecdysonereceptor (EcR) and ultraspiracle protein (USP). EcR is a member of thenuclear steroid receptor super family that is characterized by signatureDNA and ligand binding domains, and an activation domain (Koelle et al.1991, Cell, 67:59-77). EcR receptors are responsive to a number ofsteroidal compounds such as ponasterone A and muristerone A. Recently,non-steroidal compounds with ecdysteroid agonist activity have beendescribed, including the commercially available insecticidestebufenozide and methoxyfenozide that are marketed world wide by Rohmand Haas Company (see International Patent Application No.PCT/EP96/00686 and U.S. Pat. No. 5,530,028). Both analogs haveexceptional safety profiles to other organisms.

International Patent Application No. PCT/US97/05330 (WO 97/38117)discloses methods for modulating the expression of an exogenous gene inwhich a DNA construct comprising the exogenous gene and an ecdysoneresponse element is activated by a second DNA construct comprising anecdysone receptor that, in the presence of a ligand therefore, andoptionally in the presence of a receptor capable of acting as a silentpartner, binds to the ecdysone response element to induce geneexpression. The ecdysone receptor of choice was isolated from Drosophilamelanogaster. Typically, such systems require the presence of the silentpartner, preferably retinoid X receptor (RXR), in order to provideoptimum activation. In mammalian cells, insect ecdysone receptor (EcR)heterodimerizes with retinoid X receptor (RXR) and regulates expressionof target genes in a ligand dependent manner. International PatentApplication No. PCT/US98/14215 (WO 99/02683) discloses that the ecdysonereceptor isolated from the silk moth Bombyx mori is functional inmammalian systems without the need for an exogenous dimer partner.

U.S. Pat. No. 5,880,333 discloses a Drosophila melanogaster EcR andultraspiracle (USP) heterodimer system used in plants in which thetransactivation domain and the DNA binding domain are positioned on twodifferent hybrid proteins. Unfortunately, this system is not effectivefor inducing reporter gene expression in animal cells (for comparison,see Example 1.2, below).

In each of these cases, the transactivation domain and the DNA bindingdomain (either as native EcR as in International Patent Application No.PCT/US98/14215 or as modified EcR as in International Patent ApplicationNo. PCT/US97/05330) were incorporated into a single molecule and theother heterodimeric partners, either USP or RXR, were used in theirnative state.

Drawbacks of the above described EcR-based gene regulation systemsinclude a considerable background activity in the absence of ligands andthat these systems are not applicable for use in both plants and animals(see U.S. Pat. No. 5,880,333). For most applications that rely onmodulating gene expression, these EcR-based systems are undesirable.Therefore, a need exists in the art for improved systems to preciselymodulate the expression of exogenous genes in both plants and animals.Such improved systems would be useful for applications such as genetherapy, large scale production of proteins and antibodies, cell-basedhigh throughput screening assays, functional genomics and regulation oftraits in transgenic animals. Improved systems that are simple, compact,and dependent on ligands that are relatively inexpensive, readilyavailable, and of low toxicity to the host would prove useful forregulating biological systems.

Various publications are cited herein, the disclosures of which areincorporated by reference in their entireties. However, the citation ofany reference herein should not be construed as an admission that suchreference is available as “Prior Art” to the instant application.

SUMMARY OF THE INVENTION

The present invention relates to a novel ecdysone receptor-basedinducible gene expression system, novel receptor polynucleotides andpolypeptides for use in the novel inducible gene expression system, andmethods of modulating the expression of a gene within a host cell usingthis inducible gene expression system. In particular, Applicants'invention relates to an improved gene expression modulation systemcomprising a polynucleotide encoding a receptor polypeptide comprising atruncation mutation.

Specifically, the present invention relates to a gene expressionmodulation system comprising: a) a first gene expression cassette thatis capable of being expressed in a host cell comprising a polynucleotidethat encodes a first polypeptide comprising: i) a DNA-binding domainthat recognizes a response element associated with a gene whoseexpression is to be modulated; and a ligand binding domain comprising aligand binding domain from a nuclear receptor; and b) a second geneexpression cassette that is capable of being expressed in the host cellcomprising a polynucleotide sequence that encodes a second polypeptidecomprising: i) a transactivation domain; and a ligand binding domaincomprising a ligand binding domain from a nuclear receptor other than anultraspiracle receptor; wherein the DNA binding domain and thetransactivation domain are from a polypeptide other than an ecdysonereceptor, a retinoid X receptor, or an ultraspiracle receptor; whereinthe ligand binding domains from the first polypeptide and the secondpolypeptide are different and dimerize.

In a specific embodiment, the ligand binding domain of the firstpolypeptide comprises an ecdysone receptor (EcR) ligand binding domain

In another specific embodiment, the ligand binding domain of the secondpolypeptide comprises a retinoid X receptor (RXR) ligand binding domain.

In a preferred embodiment, the ligand binding domain of the firstpolypeptide comprises an ecdysone receptor ligand binding domain and theligand binding domain of the second polypeptide comprises a retinoid Xreceptor ligand binding domain

The present invention also relates to a gene expression modulationsystem according, to the invention further comprising c) a third geneexpression cassette comprising: i) a response element to which theDNA-binding domain of the first polypeptide binds; ii) a promoter thatis activated by the transactivation domain of the second polypeptide;and the gene whose expression is to be modulated.

The present invention also relates to an isolated polynucleotideencoding a truncated EcR or a truncated RXR polypeptide, wherein thetruncation mutation affects ligand binding activity or ligandsensitivity.

In particular, the present invention relates to an isolatedpolynucleotide encoding a truncated EcR or a truncated RXR polypeptidecomprising a truncation mutation that reduces ligand binding activity orligand sensitivity of said EcR or RXR polypeptide. In a specificembodiment, the present invention relates to an isolated polynucleotideencoding a truncated EcR or a truncated RXR polypeptide comprising atruncation mutation that reduces steroid binding activity or steroidsensitivity of said EcR or RXR polypeptide. In another specificembodiment, the present invention relates to an isolated polynucleotideencoding a truncated EcR or a truncated RXR polypeptide comprising atruncation mutation that reduces non-steroid binding activity ornon-steroid sensitivity of said EcR or RXR polypeptide.

The present invention also relates to an isolated polynucleotideencoding a truncated EcR or a truncated RXR polypeptide comprising atruncation mutation that enhances ligand binding activity or ligandsensitivity of said EcR or RXR polypeptide. In a specific embodiment,the present invention relates to an isolated polynucleotide encoding atruncated EcR or a truncated RXR polypeptide comprising a truncationmutation that enhances steroid binding activity or steroid sensitivityof said EcR or RXR polypeptide. In another specific embodiment, thepresent invention relates to an isolated polynucleotide encoding atruncated EcR or a truncated RXR polypeptide comprising a truncationmutation that enhances non-steroid binding activity or non-steroidsensitivity of said EcR or RXR polypeptide.

The present invention also relates to an isolated polynucleotideencoding a truncated RXR polypeptide comprising a truncation mutationthat increases ligand sensitivity of a heterodimer comprising thetruncated retinoid X receptor polypeptide and a dimerization partner. Ina specific embodiment, the dimerization partner is an ecdysone receptorpolypeptide.

The present invention also relates to an isolated polypeptide encoded bya polynucleotide according to Applicants' invention. In particular, thepresent invention relates to an isolated truncated EcR or truncated RXRpolypeptide comprising a truncation mutation, wherein the EcR or RXRpolypeptide is encoded by a polynucleotide according to the invention.

Thus, the present invention also relates to an isolated truncated EcR ortruncated RXR polypeptide comprising a truncation mutation that affectsligand binding activity or ligand sensitivity of said EcR or RXRpolypeptide.

Applicants' invention also relates to methods of modulating geneexpression in a host cell using a gene expression modulation systemaccording to the invention. Specifically, Applicants' invention providesa method of modulating the expression of a gene in a host cellcomprising the gene to be modulated comprising the steps of: a)introducing into the host cell a gene expression modulation systemaccording to the invention; and b) introducing into the host cell aligand that independently combines with the ligand binding domains ofthe first polypeptide and the second polypeptide of the gene expressionmodulation system; wherein the gene to be expressed is a component of achimeric gene comprising: i) a response element comprising a domain towhich the DNA binding domain from the first polypeptide binds; ii) apromoter that is activated by the transactivation domain of the secondpolypeptide; and the gene whose expression is to be modulated, whereby acomplex is formed comprising the ligand, the first polypeptide, and thesecond polypeptide, and whereby the complex modulates

expression of the gene in the host cell.

Applicants' invention also provides an isolated host cell comprising aninducible gene expression system according to the invention. The presentinvention also relates to an isolated host cell comprising apolynucleotide or polypeptide according to the invention. Accordingly,Applicants' invention also relates to a non-human organism comprising ahost cell according to the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: An ecdysone receptor-based gene expression, system comprising afirst gene expression cassette encoding a Gal4DBD-CfEcRDEF chimericpolypeptide and a second gene expression cassette encoding aVP16AD-MmRXRDEF chimeric polypeptide; prepared as described in Example 1(switch 1.1).

FIG. 2: An ecdysone receptor gene expression system comprising a firstgene expression cassette encoding a Gal4DBD-CfEcRDEF chimericpolypeptide and a second gene expression cassette encoding aVP16AD-CfUSPDEF Chimeric polypeptide; prepared as described in Example 1(switch 1.2).

FIG. 3: An ecdysone receptor-based gene expression system comprising afirst gene expression cassette encoding a Gal4DBD-MmRXRDEF chimericpolypeptide and a second gene expression cassette encoding aVP16AD-CfEcRCDEF chimeric polypeptide; prepared as described in Example1 (switch 1.3).

FIG. 4: An ecdysone receptor-based gene expression system comprising afirst gene expression cassette encoding a Gal4DBD-MmRXRDEF chimericpolypeptide and a second gene expression cassette encoding aVP16AD-DmEcRCDEF chimeric polypeptide; prepared as described in Example1 (switch 1.4).

FIG. 5: An ecdysone receptor-based gene expression system comprising afirst gene expression cassette encoding a Gal4DBD-CfUSPDEF chimericpolypeptide and a second gene expression cassette encoding aVP16AD-CfEcRCDEF chimeric polypeptide; prepared as described in Example1 (switch 1.5).

FIG. 6: An ecdysone receptor-based gene expression system comprising afirst gene expression cassette encoding a Gal4DBD-CfEcRDEF-VP16ADchimeric polypeptide; prepared as described in Example 1 (switch 1.6).

FIG. 7: An ecdysone receptor-based gene expression system comprising afirst gene expression cassette encoding a VP16AD-CfEcRCDEF chimericpolypeptide; prepared as described in Example 1 (switch 1.7),

FIG. 8: An ecdysone receptor-based gene expression system comprising afirst gene expression cassette encoding a VP16AD-DmEcRCDEF chimericpolypeptide and a second gene expression cassette encoding a MmRXRpolypeptide; prepared as described in Example 1 (switch 1.3).

FIG. 9: An ecdysone receptor-based gene expression system comprising afirst gene expression cassette encoding a VP16AD-CfEcRCDEF chimericpolypeptide and a second gene expression cassette encoding a MmRXRpolypeptide; prepared as described in Example 1 (switch 1.9).

FIG. 10: An ecdysone receptor-based gene expression system comprising agene expression cassette encoding a Gal4DBD-CfEcRCDEF chimericpolypeptide; prepared as described in Example 1 (switch 1.10).

FIG. 11: Expression data of GAL4CfEcRA/BCDEF, GAL4CfEcRCDEF,GAL4CfEcR1/2CDEF, GAL4CfEcRDEF, GAL4CfEcREF, GAL4CfEcRDE truncationmutants transfected into NIH3T3 cells along with VP16MmRXRDE, pFRLUc andpTKRL plasmid DNAs.

FIG. 12: Expression data of GAL4CfEcRA/BCDEF, GAL4CfEcRCDEF,GAL4CfEcR1/2CDEF, GAL4CfEcRDEF, GAL4CfEcREF, GAL4CfEcRDE truncationmutants transfected into 3T3 cells along with VP16MmRXRE, pFRLUc andpTKRL plasmid DNAs.

FIG. 13: Expression data of VP16MmRXRA/BCDEF, VP16MmRXRCDEF,VP16MmRXRDEF, VP16MmRXREF, VP16MmRXRBam-EF, VP16MmRXRAF2del constructstransfected into NIH3T3 cells along with GAL4CfEcRCDEF, pFRLUc and pTKRLplasmid DNAs.

FIG. 14: Expression data of VP16MmRXRA/BCDEF, VP16MmRXRCDEF,VP16MmRXRDEF, VP16MmRXREF, VP16MmRXRBam-EF, VP16MmRXRAF2del constructstransfected into NIH3T3 cells along with GAL4CfEcRDEF, pFRLUc and pTKRLplasmid DNAs.

FIG. 15: Expression data of various truncated CfEcR and MmRXR receptorpairs transfected into NIH3T3 cells along with GAL4CfEcRDEF, pFRLUc andpTKRL plasmid DNAs.

DETAILED DESCRIPTION OF THE INVENTION

Applicants have now developed an improved ecdysone receptor-basedinducible gene expression system comprising a truncation mutant of anecdysone receptor or a retinoid X receptor (RXR) polypeptide thataffects ligand binding activity or ligand sensitivity. This mutationaleffect may increase or reduce ligand binding activity or ligandsensitivity and may be steroid or non-steroid specific. Thus,Applicants' invention provides an improved ecdysone receptor-basedinducible gene expression system useful for modulating expression of agene of interest in a host cell. In a particularly desirable embodiment,Applicants' invention provides an inducible gene expression system thathas a reduced level of background gene expression and responds tosubmicromolar concentrations of non-steroidal ligand. Thus, Applicants'novel inducible gene expression system and its use in methods ofmodulating gene expression in a host cell overcome the limitations ofcurrently available inducible expression systems and provide the skilledartisan with an effective means to control gene expression.

The present invention provides a novel inducible gene expression systemthat can be used to modulate gene expression in both prokaryotic andeukaryotic host cells. Applicants' invention is useful for applicationssuch as gene therapy, large scale production of proteins and antibodies,cell-based high throughput screening assays, functional genomics andregulation of traits in transgenic organisms.

Definitions

In this disclosure, a number of terms and abbreviations are used. Thefollowing definitions are provided and should be helpful inunderstanding the scope and practice of the present invention.

In a specific embodiment, the term “about” or “approximately” meanswithin 20%, preferably within 10%, more preferably within 5%, and evenmore preferably within 1% of a given value or range.

The term “substantially free” means that a composition comprising “A”(where “A” is a single protein, DNA molecule, vector, recombinant hostcell, etc.) is substantially free of “B” (where “B” comprises one ormore contaminating proteins, DNA molecules, vectors, etc.) when at leastabout 75% by weight of the proteins, DNA, vectors (depending on thecategory of species to which A and B belong) in the composition is “A”.Preferably, “A” comprises at least about 90% by weight of the A+Bspecies in the composition, most preferably at least about 99% byweight. It is also preferred that a composition, which is substantiallyfree of contamination, contain only a single molecular weight specieshaving the activity or characteristic of the species of interest.

The term “isolated” for the purposes of the present invention designatesa biological material (nucleic acid or protein) that has been removedfrom its original environment (the environment in which it is naturallypresent).

For example, a polynucleotide present in the natural state in a plant oran animal is not isolated. The same polynucleotide separated from theadjacent nucleic acids in which it is naturally present. The term“purified” does not require the material to be present in a formexhibiting absolute purity, exclusive of the presence of othercompounds. It is rather a relative definition.

A polynucleotide is in the “purified” state after purification of thestarting material or of the natural material by at least one order ofmagnitude, preferably 2 or 3 and preferably 4 or 5 orders of magnitude.

A “nucleic acid” is a polymeric compound comprised of covalently linkedsubunits called nucleotides. Nucleic acid includes polyribonucleic acid(RNA) and polydeoxyribonucleic acid (DNA), both of which may besingle-stranded or double-stranded. DNA includes but is not limited tocDNA, genomic DNA, plasmids DNA, synthetic DNA, and semi-synthetic DNA.DNA may be linear, circular, or supercoiled.

A “nucleic acid molecule” refers to the phosphate ester polymeric formof ribonucleosides (adenosine, guanosine, uridine or cytidine; “RNAmolecules”) or deoxyribonucleosides (deoxyadenosine, deoxyguanosine,deoxythymidine, or deoxycytidine; “DNA molecules”), or any phosphoesteranologs thereof, such as phosphorothioates and thioesters, in eithersingle stranded form, or a double-stranded helix. Double strandedDNA-DNA, DNA-RNA and RNA-RNA helices are possible. The term nucleic acidmolecule, and in particular DNA or RNA molecule, refers only to theprimary and secondary structure of the molecule, and does not limit itto any particular tertiary forms. Thus, this term includesdouble-stranded DNA found, inter alia, in linear or circular DNAmolecules (e.g., restriction fragments), plasmids, and chromosomes. Indiscussing the structure of particular double-stranded DNA molecules,sequences may be described herein according to the normal convention ofgiving only the sequence in the 5′ to 3′ direction along thenon-transcribed strand of DNA (i.e., the strand having a sequencehomologous to the mRNA). A “recombinant DNA molecule” is a DNA moleculethat has undergone a molecular biological manipulation.

The term “fragment” will be understood to mean a nucleotide sequence ofreduced length relative to the reference nucleic acid and comprising,over the common portion, a nucleotide sequence identical to thereference nucleic acid. Such a nucleic acid fragment according to theinvention may be, where appropriate, included in a larger polynucleotideof which it is a constituent. Such fragments comprise, or alternativelyconsist of, oligonucleotides ranging in length from at least 8, 10, 12,15, 18, 20 to 25, 30, 40, 50, 70, 80, 100, 200, 500, 1000 or 1500consecutive nucleotides of a nucleic acid according to the invention.

As used herein, an “isolated nucleic acid fragment” is a polymer of RNAor DNA that is single- or double-stranded, optionally containingsynthetic, non-natural or altered nucleotide bases. An isolated nucleicacid fragment in the form of a polymer of DNA may be comprised of one ormore segments of cDNA, genomic DNA or synthetic DNA.

A “gene” refers to an assembly of nucleotides that encode a polypeptide,and includes cDNA and genomic DNA nucleic acids. “Gene” also refers to anucleic acid fragment that expresses a specific protein or polypeptide,including regulatory sequences preceding (5′ non-coding sequences) andfollowing (3′ non-coding sequences) the coding sequence. “Native gene”refers to a gene as found in nature with its own regulatory sequences.“Chimeric gene” refers to any gene that is not a native gene, comprisingregulatory and/or coding sequences that are not found together innature. Accordingly, a chimeric gene may comprise regulatory sequencesand coding sequences that are derived from different sources, orregulatory sequences and coding sequences derived from the same source,but arranged in a manner different than that found in nature. A chimericgene may comprise coding sequences derived from different sources and/orregulatory sequences derived from different sources. “Endogenous gene”refers to a native gene in its natural location in the genome of anorganism. A “foreign” gene or “heterologous” gene refers to a gene notnormally found in the host organism, but that is introduced into thehost organism by gene transfer. Foreign genes can comprise native genesinserted into a non-native organism, or chimeric genes. A “transgene” isa gene that has been introduced into the genome by a transformationprocedure.

“Heterologous” DNA refers to DNA not naturally located in the cell, orin a chromosomal site of the cell. Preferably, the heterologous DNAincludes a gene foreign to the cell.

The term “genome” includes chromosomal as well as mitochondrial,chloroplast and viral DNA or RNA.

A nucleic acid molecule is “hybridizable” to another nucleic acidmolecule, such as a cDNA, genomic DNA, or RNA, when a single strandedform of the nucleic acid molecule can anneal to the other nucleic acidmolecule under the appropriate conditions of temperature and solutionionic strength (see Sambrook et al., 1989 infra). Hybridization andwashing conditions are well known and exemplified in Sambrook, J.,Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual,Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor(1989), particularly Chapter 11 and Table 11.1 therein (entirelyincorporated herein by reference). The conditions of temperature andionic strength determine the “stringency” of the hybridization.

Stringency conditions can be adjusted to screen for moderately similarfragments, such as homologous sequences from distantly relatedorganisms, to highly similar fragments, such as genes that duplicatefunctional enzymes from closely related organisms. For preliminaryscreening for homologous nucleic acids, low stringency hybridizationconditions, corresponding to a T_(m) of 55°, can be used, e.g., 5×SSC,0.1% SDS, 0.25% milk, and no formamide; or 30% formamide, 5×SSC, 0.5%SDS). Moderate stringency hybridization conditions correspond to ahigher T_(m), e.g., 40% formamide, with 5× or 6×SCC. High stringencyhybridization conditions correspond to the highest T_(m), e.g., 50%formamide, 5× or 6×SCC. Hybridization requires that the two nucleicacids contain complementary sequences, although depending on thestringency of the hybridization, mismatches between bases are possible.

The term “complementary” is used to describe the relationship betweennucleotide bases that are capable of hybridizing to one another. Forexample, with respect to DNA, adenosine is complementary to thymine andcytosine is complementary to guanine. Accordingly, the instant inventionalso includes isolated nucleic acid fragments that are complementary tothe complete sequences as disclosed or used herein as well as thosesubstantially similar nucleic acid sequences.

In a specific embodiment, the term “standard hybridization conditions”refers to a T_(m) of 55° C., and utilizes conditions as set forth above.In a preferred embodiment, the T_(m) is 60° C.; in a more preferredembodiment, the T_(m) is 65° C.

Post-hybridization washes also determine stringency conditions. One setof preferred conditions uses a series of washes starting with 6×SSC,0.5% SDS at room temperature for 15 minutes (min), then repeated with2×SSC, 0.5% SDS at 45° C. for 30 minutes, and then repeated twice with0.2×SSC, 0.5% SDS at 50° C. for 30 minutes. A more preferred set ofstringent conditions uses higher temperatures in which the washes areidentical to those above except for the temperature of the final two 30min washes in 0.2×SSC, 0.5% SDS was increased to 60° C. Anotherpreferred set of highly stringent conditions uses two final washes in0.1×SSC, 0.1% SDS at 65° C. Hybridization requires that the two nucleicacids comprise complementary sequences, although depending on thestringency of the hybridization, mismatches between bases are possible.

The appropriate stringency for hybridizing nucleic acids depends on thelength of the nucleic acids and the degree of complementation, variableswell known in the art. The greater the degree of similarity or homologybetween two nucleotide sequences, the greater the value of T_(m) forhybrids of nucleic acids having those sequences. The relative stability(corresponding to higher T_(m)) of nucleic acid hybridizations decreasesin the following order: RNA:RNA, DNA:RNA, DNA:DNA. For hybrids ofgreater than 100 nucleotides in length, equations for calculating T_(m)have been derived (see Sambrook et al., supra, 9.50-0.51). Forhybridization with shorter nucleic acids, i.e., oligonucleotides, theposition of mismatches becomes more important, and the length of theoligonucleotide determines its specificity (see Sambrook at al., supra,11.7-11.8).

In one embodiment the length for a hybridizable nucleic acid is at leastabout 10 nucleotides. Preferable a minimum length for a hybridizablenucleic acid is at least about 15 nucleotides; more preferably at leastabout 20 nucleotides; and most preferably the length is at least 30nucleotides. Furthermore, the skilled artisan will recognize that thetemperature and wash solution salt concentration may be adjusted asnecessary according to factors such as length of the probe.

The term “probe” refers to a single-stranded nucleic acid molecule thatcan base pair with a complementary single stranded target nucleic acidto form a double-stranded molecule.

As used herein, the term “oligonucleotide” refers to a nucleic acid,generally of at least 18 nucleotides, that is hybridizable to a genomicDNA molecule, a cDNA molecule, a plasmid DNA or an mRNA molecule.Oligonucleotides can be labeled, e.g., with ³²P-nucleotides ornucleotides to which a label, such as biotin, has been covalentlyconjugated. A labeled oligonucleotide can be used as a probe to detectthe presence of a nucleic acid. Oligonucleotides (one or both of whichmay be labeled) can be used as PCR primers, either for cloning fulllength or a fragment of a nucleic acid, or to detect the presence of anucleic acid. An oligonucleotide can also be used to form a triple helixwith a DNA molecule. Generally, oligonucleotides are preparedsynthetically, preferably on a nucleic acid synthesizer. Accordingly,oligonucleotides can be prepared with non-naturally occurringphosphoester analog bonds, such as thioester bonds, etc.

A “primer” is an oligonucleotide that hybridizes to a target nucleicacid sequence to create a double stranded nucleic acid region that canserve as an initiation point for DNA synthesis under suitableconditions. Such primers may be used in a polymerase chain reaction.

“Polymerase chain reaction” is abbreviated PCR and means an in vitromethod for enzymatically amplifying specific nucleic acid sequences. PCRinvolves a repetitive series of temperature cycles with each cyclecomprising three stages: denaturation of the template nucleic acid toseparate the strands of the target molecule, annealing a single strandedPCR oligonucleotide primer to the template nucleic acid, and extensionof the annealed primer(s) by DNA polymerase. PCR provides a means todetect the presence of the target molecule and, under quantitative orsemi-quantitative conditions, to determine the relative amount of thattarget molecule within the starting pool of nucleic acids.

“Reverse transcription-polymerase chain reaction” is abbreviated RT-PCRand means an in vitro method for enzymatically producing a target cDNAmolecule or molecules from an RNA molecule or molecules, followed byenzymatic amplification of a specific nucleic acid sequence or sequenceswithin the target cDNA molecule or molecules as described above. RT-PCRalso provides a means to detect the presence of the target molecule and,under quantitative or semi-quantitative conditions, to determine therelative amount of that target molecule within the starting pool ofnucleic acids.

A DNA “coding sequence” is a double-stranded DNA sequence that istranscribed and translated into a polypeptide in a cell in vitro or invivo when placed under the control of appropriate regulatory sequences.“Suitable regulatory sequences” refer to nucleotide sequences locatedupstream (5′ non-coding sequences), within, or downstream (3′ non-codingsequences) of a coding sequence, and which influence the transcription,RNA processing or stability, or translation of the associated codingsequence. Regulatory sequences may include promoters, translation leadersequences, introns, polyadenylation recognition sequences, RNAprocessing site, effector binding site and stem-loop structure. Theboundaries of the coding sequence are determined by a start codon at the5′ (amino) terminus and a translation stop codon at the 3′ (carboxyl)terminus. A coding sequence can include, but is not limited to,prokaryotic sequences, cDNA from mRNA, genomic DNA sequences, and evensynthetic DNA sequences. If the coding sequence is intended forexpression in a eukaryotic cell, a polyadenylation signal andtranscription termination sequence will usually be located 3′ to thecoding sequence.

“Open reading frame” is abbreviated ORF and means a length of nucleicacid sequence, either DNA, cDNA or RNA, that comprises a translationstart signal or initiation codon, such as an ATG or AUG, and atermination codon and can be potentially translated into a polypeptidesequence.

The term “head-to-head” is used herein to describe the orientation oftwo polynucleotide sequences in relation to each other. Twopolynucleotides are positioned in a head-to-head orientation when the 5′end of the coding strand of one polynucleotide is adjacent to the 5′ endof the coding strand of the other polynucleotide, whereby the directionof transcription of each polynucleotide proceeds away from the 5′ end ofthe other polynucleotide. The term “head-to-head” may be abbreviated(5′)-to-(5′) and may also be indicated by the symbols (← →) or(3′←5′5′→3′).

The term “tail-to-tail” is used herein to describe the orientation oftwo polynucleotide sequences in relation to each other. Twopolynucleotides are positioned in a tail-to-tail orientation when the 3′end of the coding strand of one polynucleotide is adjacent to the 3′ endof the coding strand of the other polynucleotide, whereby the directionof transcription of each polynucleotide proceeds toward the otherpolynucleotide. The term “tail-to-tail” may be abbreviated (3′)-to-(3′)and may also be indicated by the symbols (→ ←) or (5′→3′3′←5′).

The “head-to-tail” is used herein to describe the orientation of twopolynucleotide sequences in relation to each other. Two polynucleotidesare positioned in a head-to-tail orientation when the 5′ end of thecoding strand of one polynucleotide is adjacent to the 3′ end of thecoding strand of the other polynucleotide, whereby the direction oftranscription of each polynucleotide proceeds in the same direction asthat of the other polynucleotide. The term “head-to-tail” may beabbreviated (5′)-to-(3′) and may also be indicated by the symbols (→ ←)or (5′→3′5′→3′).

The term “downstream” refers to a nucleotide sequence that is located 3′to reference nucleotide sequence. In particular, downstream nucleotidesequences generally relate to sequences that follow the starting pointof transcription. For example, the translation initiation codon of agene is located downstream of the start site of transcription.

The term “upstream” refers to a nucleotide sequence that is located 5′to reference nucleotide sequence. In particular, upstream nucleotidesequences generally relate to sequences that are located on the 5′ sideof a coding sequence or starting point of transcription. For example,most promoters are located upstream of the start site of transcription.

The terms “restriction endonuclease” and “restriction enzyme” refer toan enzyme that binds and cuts within a specific nucleotide sequencewithin double stranded DNA.

“Homologous recombination” refers to the insertion of a foreign DNAsequence into another DNA molecule, e.g., insertion of a vector in achromosome. Preferably, the vector targets a specific chromosomal sitefor homologous recombination. For specific homologous recombination, thevector will contain sufficiently long regions of homology to sequencesof the chromosome to allow complementary binding and incorporation ofthe vector into the chromosome. Longer regions of homology, and greaterdegrees of sequence similarity, may increase the efficiency ofhomologous recombination.

Several methods known in the art may be used to propagate apolynucleotide according to the invention. Once a suitable host systemand growth conditions are established, recombinant expression vectorscan be propagated and prepared in quantity. As described herein, theexpression vectors which can be used include, but are not limited to,the following vectors or their derivatives: human or animal viruses suchas vaccinia virus or adenovirus; insect viruses such as baculovirus;yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid andcosmid DNA vectors, to name but a few.

A “vector” is any means for the cloning of and/or transfer of a nucleicacid into a host cell. A vector may be a replicon to which another DNAsegment may be attached so as to bring about the replication of theattached segment. A “replicon” is any genetic element (e.g., plasmid,phage, cosmid, chromosome, virus) that functions as an autonomous unitof DNA replication in vivo, i.e., capable of replication under its owncontrol. The term “vector” includes both viral and nonviral means forintroducing the nucleic acid into a cell in vitro, ex vivo or in vivo. Alarge number of vectors known in the art may be used to manipulatenucleic acids, incorporate response elements and promoters into genes,etc. Possible vectors include, for example, plasmids or modified virusesincluding, for example bacteriophages such as lambda derivatives, orplasmids such as PBR322 or pUC plasmid derivatives, or the Bluescriptvector. For example, the insertion of the DNA fragments corresponding toresponse elements and promoters into a suitable vector can beaccomplished by ligating the appropriate DNA fragments into a chosenvector that has complementary cohesive termini. Alternatively, the endsof the DNA molecules may be enzymatically modified or any site may beproduced by ligating nucleotide sequences (linkers) into the DNAtermini. Such vectors may be engineered to contain selectable markergenes that provide for the selection of cells that have incorporated themarker into the cellular genome. Such markers allow identificationand/or selection of host cells that incorporate and express the proteinsencoded by the marker.

Viral vectors, and particularly retroviral vectors, have been used in awide variety of gene delivery applications in cells, as well as livinganimal subjects. Viral vectors that can be used include but are notlimited to retrovirus, adeno-associated virus, pox, baculovirus,vaccinia, herpes simplex, Epstein-Barr, adenovirus, geminivirus, andcaulimovirus vectors. Non-viral vectors include plasmids, liposomes,electrically charged lipids (cytofectins), DNA-protein complexes, andbiopolymers. In addition to a nucleic acid, a vector may also compriseone or more regulatory regions, and/or selectable markers useful inselecting, measuring, and monitoring nucleic acid transfer results(transfer to which tissues, duration of expression, etc.).

The term “plasmid” refers to an extra chromosomal element often carryinga gene that is not part of the central metabolism of the cell, andusually in the form of circular double-stranded DNA molecules. Suchelements may be autonomously replicating sequences, genome integratingsequences, phage or nucleotide sequences, linear, circular, orsupercoiled, of a single- or double-stranded DNA or RNA, derived fromany source, in which a number of nucleotide sequences have been joinedor recombined into a unique construction which is capable of introducinga promoter fragment and DNA sequence for a selected gene product alongwith appropriate 3′ untranslated sequence into a cell.

A “cloning vector” is a “replicon”, which is a unit length of a nucleicacid, preferably DNA, that replicates sequentially and which comprisesan origin of replication, such as a plasmid, phage or cosmid, to whichanother nucleic acid segment may be attached so as to bring about thereplication of the attached segment. Cloning vectors may be capable ofreplication in one cell type and expression in another (“shuttlevector”).

Vectors may be introduced into the desired host cells by methods knownin the art, e.g., transfection, electroporation, microinjection,transduction, cell fusion, DEAE dextran calcium phosphate precipitation,lipofection (lysosome fusion), use of a gene gun, or a DNA vectortransporter (see, e.g., Wu et al., 1992, J. Biol. Chem. 267:963-967; Wuand Wu, 1988, J. Biol. Chem. 263:14621-14624; and Hartmut et al.,Canadian Patent Application No. 2,012,311, filed Mar. 15, 1990).

A polynucleotide according to the invention can also be introduced invivo by lipofection. For the past decade, there has been increasing useof liposomes for encapsulation and transfection of nucleic acids invitro. Synthetic cationic lipids designed to limit the difficulties anddangers encountered with liposome mediated transfection can be used toprepare liposomes for in vivo transfection of a gene encoding a marker(Feigner et al., 1987. PNAS 84:7413; Mackey, et al., 1988. Proc. Natl.Acad. Sci. U.S.A. 85:8027-8031; and Ulmer et al., 1993. Science259:1745-1748). The use of cationic lipids may promote encapsulation ofnegatively charged nucleic acids, nucleic acids, and also promote fusionwith negatively charged cell membranes (Feigner and Ringold, 1989.Science 337:387-388). Particularly useful lipid compounds andcompositions for transfer of nucleic acids are described inInternational Patent Publications WO95/18863 and WO96/17823, and in U.S.Pat. No. 5,459,127. The use of lipofection to introduce exogenous genesinto the specific organs in vivo has certain practical advantages.Molecular targeting of liposomes to specific cells represents one areaof benefit. It is clear that directing transfection to particular celltypes would be particularly preferred in a tissue with cellularheterogeneity, such as pancreas, liver, kidney, and the brain. Lipidsmay be chemically coupled to other molecules for the purpose oftargeting (Mackey, et al., 1988, supra). Targeted peptides, e.g.,hormones or neurotransmitters, and proteins such as antibodies, ornon-peptide molecules could be coupled to liposomes chemically.

Other molecules are also useful for facilitating transfection of anucleic acid in vivo, such as a cationic oligopeptide (e.g.,WO95/21931), peptides derived from DNA binding proteins (e.g.,WO96/25508), or a cationic polymer (e.g., WO95/21931).

It is also possible to introduce a vector in vivo as a naked DNA plasmid(see U.S. Pat. Nos. 5,693,622, 5,589,466 and 5,580,859).Receptor-mediated DNA delivery approaches can also be used (Curiel etal., 1992. Hum. Gene Ther. 3:147-154; and Wu and Wu, 1987. J. Biol.Chem. 262:4429-4432).

The term “transfection” means the uptake of exogenous or heterologousRNA or DNA by a cell. A cell has been “transfected” by exogenous orheterologous RNA or DNA when such RNA or DNA has been introduced insidethe cell. A cell has been “transformed” by exogenous or heterologous RNAor DNA when the transfected RNA or DNA effects a phenotypic change. Thetransforming RNA or DNA can be integrated (covalently linked) intochromosomal DNA making up the genome of the cell.

“Transformation” refers to the transfer of a nucleic acid fragment intothe genome of a host organism, resulting in genetically stableinheritance. Host organisms containing the transformed nucleic acidfragments are referred to as “transgenic” or “recombinant” or“transformed” organisms.

The term “genetic region” will refer to a region of a nucleic acidmolecule or a nucleotide sequence that comprises a gene encoding apolypeptide.

In addition, the recombinant vector comprising a polynucleotideaccording to the invention may include one or more origins forreplication in the cellular hosts in which their amplification or theirexpression is sought, markers or selectable markers.

The term “selectable marker” means an identifying factor, usually anantibiotic or chemical resistance gene, that is able to be selected forbased upon the marker gene's effect, i.e., resistance to an antibiotic,resistance to a herbicide, colorimetric markers, enzymes, fluorescentmarkers, and the like, wherein the effect is used to track theinheritance of a nucleic acid of interest and/or to identify a cell ororganism that has inherited the nucleic acid of interest. Examples ofselectable marker genes known and used in the art include: genesproviding resistance to ampicillin, streptomycin, gentamycin, kanamycin,hygromycin, bialaphos herbicide, sulfonamide, and the like; and genesthat are used as phenotypic markers, i.e., anthocyanin regulatory genes,isopentanyl transferase gene, and the like.

The term “reporter gene” means a nucleic acid encoding an identifyingfactor that is able to be identified based upon the reporter gene'seffect wherein the effect is used to track the inheritance of a nucleicacid of interest, to identify a cell or organism that has inherited thenucleic acid of interest, and/or to measure gene expression induction ortranscription. Examples of reporter genes known and used in the artinclude: luciferase (Luc), green fluorescent protein (GFP),chloramphenicol acetyltransferase (CAT), β-galactosidase (LacZ),β-glucuronidase (Gus), and the like. Selectable marker genes may also beconsidered reporter genes.

“Promoter” refers to a DNA sequence capable of controlling theexpression of a coding sequence or functional RNA. In general, a codingsequence is located 3′ to a promoter sequence. Promoters may be derivedin their entirety from a native gene, or be composed of differentelements derived from different promoters found in nature, or evencomprise synthetic DNA segments. It is understood by those skilled inthe art that different promoters may direct the expression of a gene indifferent tissues or cell types, or at different stages of development,or in response to different environmental or physiological conditions.Promoters that cause a gene to be expressed in most cell types at mosttimes are commonly referred to as “constitutive promoters”. Promotersthat cause a gene to be expressed in a specific cell type are commonlyreferred to as “cell-specific promoters” or “tissue-specific promoters”.Promoters that cause a gene to be expressed at a specific stage ofdevelopment or cell differentiation are commonly referred to as“developmentally-specific promoters” or “cell differentiation-specificpromoters”. Promoters that are induced and cause a gene to be expressedfollowing exposure or treatment of the cell with an agent, biologicalmolecule, chemical, ligand, light, or the like that induces the promoterare commonly referred to as “inducible promoters” or “regulatablepromoters”. It is further recognized that since in most cases the exactboundaries of regulatory sequences have not been completely defined, DNAfragments of different lengths may have identical promoter activity.

A “promoter sequence” is a DNA regulatory region capable of binding RNApolymerase in a cell and initiating transcription of a downstream (3′direction) coding sequence. For purposes of defining the presentinvention, the promoter sequence is bounded at its 3′ terminus by thetranscription initiation site and extends upstream (5′ direction) toinclude the minimum number of bases or elements necessary to initiatetranscription at levels detectable above background. Within the promotersequence will be found a transcription initiation site (convenientlydefined for example, by mapping with nuclease S1), as well as proteinbinding domains (consensus sequences) responsible for the binding of RNApolymerase.

A coding sequence is “under the control” of transcriptional andtranslational control sequences in a cell when RNA polymerasetranscribes the coding sequence into mRNA, which is then trans-RNAspliced (if the coding sequence contains introns) and translated intothe protein encoded by the coding sequence.

“Transcriptional and translational control sequences” are DNA regulatorysequences, such as promoters, enhancers, terminators, and the like, thatprovide for the expression of a coding sequence in a host cell. Ineukaryotic cells, polyadenylation signals are control sequences.

The term “response element” means one or more cis-acting DNA elementswhich confer responsiveness on a promoter mediated through interactionwith the DNA-binding domains of the first chimeric gene. This DNAelement may be either palindromic (perfect or imperfect) in its sequenceor composed of sequence motifs or half sites separated by a variablenumber of nucleotides. The half sites can be similar or identical andarranged as either direct or inverted repeats or as a single half siteor multimers of adjacent half sites in tandem. The response element maycomprise a minimal promoter isolated from different organisms dependingupon the nature of the cell or organism into which the response elementwill be incorporated. The DNA binding domain of the first hybrid proteinbinds, in the presence or absence of a ligand, to the DNA sequence of aresponse element to initiate or suppress transcription of downstreamgene(s) under the regulation of this response element. Examples of DNAsequences for response elements of the natural ecdysone receptorinclude: RRGG/TTCANTGAC/ACYY (see Cherbas L., et. al., (1991), GenesDev. 5, 120-131); AGGTCAN_((n))AGGTCA, where N_((n)) can be one or morespacer nucleotides (see D'Avino P P., et. al., (1995), Mol. Cell.Endocrinol, 113, 1-9); and GGGTTGAATGAATTT (see Antoniewski C., et. al.,(1994). Mol. Cell Biol. 14, 4465-4474).

The term “operably linked” refers to the association of nucleic acidsequences on a single nucleic acid fragment so that the function of oneis affected by the other. For example, a promoter is operably linkedwith a coding sequence when it is capable of affecting the expression ofthat coding sequence (i.e., that the coding sequence is under thetranscriptional control of the promoter). Coding sequences can beoperably linked to regulatory sequences in sense or antisenseorientation.

The term “expression”, as used herein, refers to the transcription andstable accumulation of sense (mRNA) or antisense RNA derived from anucleic acid or polynucleotide. Expression may also refer to translationof mRNA into a protein or polypeptide.

The terms “cassette”, “expression cassette” and “gene expressioncassette” refer to a segment of DNA that can be inserted into a nucleicacid or polynucleotide at specific restriction sites or by homologousrecombination. The segment of DNA comprises a polynucleotide thatencodes a polypeptide of interest, and the cassette and restrictionsites are designed to ensure insertion of the cassette in the properreading frame for transcription and translation. “Transformationcassette” refers to a specific vector comprising a polynucleotide thatencodes a polypeptide of interest and having elements in addition to thepolynucleotide that facilitate transformation of a particular host cell.Cassettes, expression cassettes, gene expression cassettes andtransformation cassettes of the invention may also comprise elementsthat allow for enhanced expression of a polynucleotide encoding apolypeptide of interest in a host cell. These elements may include, butare not limited to: a promoter, a minimal promoter, an enhancer, aresponse element, a terminator sequence, a polyadenylation sequence, andthe like.

For purposes of this invention, the term “gene switch” refers to thecombination of a response element associated with a promoter, and an EcRbased system which, in the presence of one or more ligands, modulatesthe expression of a gene into which the response element and promoterare incorporated.

The terms “modulate” and “modulates” mean to induce, reduce or inhibitnucleic acid or gene expression, resulting in the respective induction,reduction or inhibition of protein or polypeptide production.

The plasmids or vectors according to the invention may further compriseat least one promoter suitable for driving expression of a gene in ahost cell. The term “expression vector” means a vector, plasmid orvehicle designed to enable the expression of an inserted nucleic acidsequence following transformation into the host. The cloned gene, i.e.,the inserted nucleic acid sequence, is usually placed under the controlof control elements such as a promoter, a minimal promoter, an enhancer,or the like. Initiation control regions or promoters, which are usefulto drive expression of a nucleic acid in the desired host cell arenumerous and familiar to those skilled in the art. Virtually anypromoter capable of driving these genes is suitable for the presentinvention including but not limited to: viral promoters, plantpromoters, bacterial promoters, animal promoters, mammalian promoters,synthetic promoters, constitutive promoters, tissue specific promoter,developmental specific promoters, inducible promoters, light regulatedpromoters; CYC1, HIS3, GAL1, GAL4, GAL10, ADH1, PGK, PHO5, GAPDH, ADC1,TRP1, URA3, LEU2, ENO, TPI, alkaline phosphatase promoters (useful forexpression in Saccharomyces); AOX1 promoter (useful for expression inPichia); b-lactamase, lac, ara, tet, trp, lP_(L), lP_(R), T7, tac, andtrc promoters (useful for expression in Escherichia coli); and lightregulated-, seed specific-, pollen specific-, ovary specific-,pathogenesis or disease related-, cauliflower mosaic virus 35S, CMV 35Sminimal, cassava vein mosaic virus (CsVMV), chlorophyll a/b bindingprotein, ribulose 1,5-bisphosphate carboxylase, shoot-specific, rootspecific, chitinase, stress inducible, rice tungro bacilliform virus,plant super-promoter, potato leucine aminopeptidase, nitrate reductase,mannopine synthase, nopaline synthase, ubiquitin, zein protein, andanthocyanin promoters (useful for expression in plant cells); animal andmammalian promoters known in the art include, but are not limited to,the SV40 early (SV40e) promoter region, the promoter contained in the 3′long terminal repeat (LTR) of Rous sarcoma virus (RSV), the promoters ofthe E1A or major late promoter (MLP) genes of adenoviruses, thecytomegalovirus early promoter, the herpes simplex virus (HSV) thymidinekinase (TK) promoter, an elongation factor 1 alpha (EF1) promoter, aphosphoglycerate kinase (PGK) promoter, a ubiquitin (Ubc) promoter, analbumin promoter, the regulatory sequences of the mousemetallothionein-L promoter, and transcriptional control regions, theubiquitous promoters (HPRT, vimentin, α-actin, tubulin and the like),the promoters of the intermediate filaments (desmin, neurofilaments,keratin, GFAP, and the like), the promoters of therapeutic genes (of theMDR, CFIR or factor VIII type, and the like), and promoters that exhibittissue specificity and have been utilized in transgenic animals, such asthe elastase I gene control region which is active in pancreatic acinarcells; insulin gene control region active in pancreatic beta cells,immunoglobulin gene control region active in lymphoid cells, mousemammary tumor virus control region active in testicular, breast,lymphoid and mast cells; albumin gene, Apo AI and Apo AII controlregions active in liver, alpha-fetoprotein gene control region active inliver, alpha 1-antitrypsin gene control region active in the liver,beta-globin gene control region active in myeloid cells, myelin basicprotein gene control region active in oligodendrocyte cells in thebrain, myosin light chain-2 gene control region active in skeletalmuscle, and gonadotropic releasing hormone gene control region active inthe hypothalamus, pyruvate kinase promoter, villin promoter, promoter ofthe fatty acid binding intestinal protein, promoter of the smooth musclecell α-actin, and the like. In a preferred embodiment of the invention,the promoter is selected from the group consisting of a cauliflowermosaic virus 35S promoter, a cassava vein mosaic virus promoter, and acauliflower mosaic virus 35S minimal promoter, an elongation factor 1alpha (EF1) promoter, a phosphoglycerate kinase (PGK) promoter, aubiquitin (Ubc) promoter, and an albumin promoter. In addition, theseexpression sequences may be modified by addition of enhancer orregulatory sequences and the like.

Enhancers that may be used in embodiments of the invention include butare not limited to: tobacco mosaic virus enhancer, cauliflower mosaicvirus 35S enhancer, tobacco etch virus enhancer, ribulose1,5-bisphosphate carboxylase enhancer, rice tungro bacilliform virusenhancer, and other plant and viral gene enhancers, and the like.

Termination control regions, i.e., terminator or polyadenylationsequences, may also be derived from various genes native to thepreferred hosts. Optionally, a termination site may be unnecessary,however, it is most preferred if included. In a preferred embodiment ofthe invention, the termination control region may be comprise or bederived from a synthetic sequence, synthetic polyadenylation signal, anSV40 late polyadenylation signal, an SV40 polyadenylation signal, abovine growth hormone (BGH) polyadenylation signal, nopaline synthase(nos), cauliflower mosaic virus (CaMV), octopine synthase (ocs),Agrocateum, viral, and plant terminator sequences, or the like.

The terms “3′ non-coding sequences” or “3′ untranslated region (UTR)”refer to DNA sequences located downstream (3′) of a coding sequence andmay comprise polyadenylation [poly(A)] recognition sequences and othersequences encoding regulatory signals capable of affecting mRNAprocessing or gene expression. The polyadenylation signal, is usuallycharacterized by affecting the addition of polyadenylic acid tracts tothe 3′ end of the mRNA precursor.

“Regulatory region” means a nucleic acid sequence which regulates theexpression of a second nucleic acid sequence. A regulatory region mayinclude sequences which are naturally responsible for expressing aparticular nucleic acid (a homologous region) or may include sequencesof a different origin that are responsible for expressing differentproteins or even synthetic proteins (a heterologous region). Inparticular, the sequences can be sequences of prokaryotic, eukaryotic,or viral genes or derived sequences that stimulate or represstranscription of a gene in a specific or non-specific manner and in aninducible or non-inducible manner. Regulatory regions include origins ofreplication, RNA splice sites, promoters, enhancers, transcriptionaltermination sequences, and signal sequences which direct the polypeptideinto the secretory pathways of the target cell.

A regulatory region from a “heterologous source” is a regulatory regionthat is not naturally associated with the expressed nucleic acid.Included among the heterologous regulatory regions are regulatoryregions from a different species, regulatory regions from a differentgene, hybrid regulatory sequences, and regulatory sequences which do notoccur in nature, but which are designed by one having ordinary skill inthe art.

“RNA transcript” refers to the product resulting from RNApolymerase-catalyzed transcription of a DNA sequence. When the RNAtranscript is a perfect complementary copy of the DNA sequence, it isreferred to as the primary transcript or it may be a RNA sequencederived from post-transcriptional processing of the primary transcriptand is referred to as the mature RNA. “Messenger RNA (mRNA)” refers tothe RNA that is without introns and that can be translated into proteinby the cell. “cDNA” refers to a double-stranded DNA that iscomplementary to and derived from mRNA. “Sense” RNA refers to RNAtranscript that includes the mRNA and so can be translated into proteinby the cell. “Antisense RNA” refers to a RNA transcript that iscomplementary to all or part of a target primary transcript or mRNA andthat blocks the expression of a target gene. The complementarity of anantisense RNA may be with any part of the specific gene transcript,i.e., at the 5′ non-coding sequence, 3′ non-coding sequence, or thecoding sequence. “Functional RNA” refers to antisense RNA, ribozyme RNA,or other RNA that is not translated yet has an effect on cellularprocesses.

A “polypeptide” is a polymeric compound comprised of covalently linkedamino acid residues. Amino acids have the following general structure:

Amino acids are classified into seven groups on the basis of the sidechain R: (1) aliphatic side chains, (2) side chains containing ahydroxylic (OH) group, (3) side chains containing sulfur atoms, (4) sidechains containing an acidic or amide group, (5) side chains containing abasic group, (6) side chains containing an aromatic ring, and (7)proline, an imino acid in which the side chain is fused to the aminogroup. A polypeptide of the invention preferably comprises at leastabout 14 amino acids.

A “protein” is a polypeptide that performs a structural or functionalrole in a living cell.

An “isolated polypeptide” or “isolated protein” is a polypeptide orprotein that is substantially free of those compounds that are normallyassociated therewith in its natural state (e.g., other proteins orpolypeptides, nucleic acids, carbohydrates, lipids). “Isolated” is notmeant to exclude artificial or synthetic mixtures with other compounds,or the presence of impurities which do not interfere with biologicalactivity, and which may be present, for example, due to incompletepurification, addition of stabilizers, or compounding into apharmaceutically acceptable preparation.

“Fragment” of a polypeptide according to the invention will beunderstood to mean a polypeptide whose amino acid sequence is shorterthan that of the reference polypeptide and which comprises, over theentire portion with these reference polypeptides, an identical aminoacid sequence. Such fragments may, where appropriate, be included in alarger polypeptide of which they are a part. Such fragments of apolypeptide according to the invention may have a length of 10, 15, 20,30 to 40, 50, 100, 200 or 300 amino acids.

A “variant” of a polypeptide or protein is any analogue, fragment,derivative, or mutant which is derived from a polypeptide or protein andwhich retains at least one biological property of the polypeptide orprotein. Different variants of the polypeptide or protein may exist innature. These variants may be allelic variations characterized bydifferences in the nucleotide sequences of the structural gene codingfor the protein, or may involve differential splicing orpost-translational modification. The skilled artisan can producevariants having single or multiple amino acid substitutions, deletions,additions, or replacements. These variants may include, inter alia: (a)variants in which one or more amino acid residues are substituted withconservative or non-conservative amino acids, (b) variants in which oneor more amino acids are added to the polypeptide or protein, (c)variants in which one or more of the amino acids includes a substituentgroup, and (d) variants in which the polypeptide or protein is fusedwith another polypeptide such as serum albumin. The techniques forobtaining these variants, including genetic (suppressions, deletions,mutations, etc.), chemical, and enzymatic techniques, are known topersons having ordinary skill in the art. A variant polypeptidepreferably comprises at least about 14 amino acids.

A “heterologous protein” refers to a protein not naturally produced inthe cell.

A “mature protein” refers to a post-translationally processedpolypeptide; i.e., one from which any pre- or propeptides present in theprimary translation product have been removed. “Precursor” proteinrefers to the primary product of translation of mRNA; i.e., with pre-and propeptides still present. Pre- and propeptides may be but are notlimited to intracellular localization signals.

The term “signal peptide” refers to an amino terminal polypeptidepreceding the secreted mature protein. The signal peptide is cleavedfrom and is therefore not present in the mature protein. Signal peptideshave the function of directing and translocating secreted proteinsacross cell membranes. Signal peptide is also referred to as signalprotein.

A “signal sequence” is included at the beginning of the coding sequenceof a protein to be expressed on the surface of a cell. This sequenceencodes a signal peptide, N-terminal to the mature polypeptide, thatdirects the host cell to translocate the polypeptide. The term“translocation signal sequence” is used herein to refer to this sort ofsignal sequence. Translocation signal sequences can be found associatedwith a variety of proteins native to eukaryotes and prokaryotes, and areoften functional in both types of organisms

The term “homology” refers to the percent of identity between twopolynucleotide or two polypeptide moieties. The correspondence betweenthe sequence from one moiety to another can be determined by techniquesknown to the art. For example, homology can be determined by a directcomparison of the sequence information between two polypeptide moleculesby aligning the sequence information and using readily availablecomputer programs. Alternatively, homology can be determined byhybridization of polynucleotides under conditions that form stableduplexes between homologous regions, followed by digestion withsingle-stranded-specific nuclease(s) and size determination of thedigested fragments.

As used herein, the term “homologous” in all its grammatical forms andspelling variations refers to the relationship between proteins thatpossess a “common evolutionary origin,” including proteins fromsuperfamilies (e.g., the immunoglobulin superfamily) and homologousproteins from different species (e.g., myosin light chain, etc.) (Reecket al., 1987, Cell 50:667.). Such proteins (and their encoding genes)have sequence homology, as reflected by their high degree of sequencesimilarity.

Accordingly, the term “sequence similarity” in all its grammatical formsrefers to the degree of identity or correspondence between nucleic acidor amino acid sequences of proteins that may or may not share a commonevolutionary origin (see Reeck et al., 1987, Cell 50:667). As usedherein, the term “homologous” in all its grammatical forms and spellingvariations refers to the relationship between proteins that possess a“common evolutionary origin,” including proteins from superfamilies andhomologous proteins from different species (Reeck et al., supra). Suchproteins (and their encoding genes) have sequence homology, as reflectedby their high degree of sequence similarity. However, in common usageand in the instant application, the term “homologous,” when modifiedwith an adverb such as “highly,” may refer to sequence similarity andnot a common evolutionary origin.

In a specific embodiment, two DNA sequences are “substantiallyhomologous” or “substantially similar” when at least about 50%(preferably at least about 75%, and most preferably at least about 90 or95%) of the nucleotides match over the defined length of the DNAsequences. Sequences that are substantially homologous can be identifiedby comparing the sequences using standard software available in sequencedata banks, or in a Southern hybridization experiment under, forexample, stringent conditions as defined for that particular system.Defining appropriate hybridization conditions is within the skill of theart. See, e.g., Sambrook et al., 1989, supra.

As used herein, “substantially similar” refers to nucleic acid fragmentswherein changes in one or more nucleotide bases results in substitutionof one or more amino acids, but do not affect the functional propertiesof the protein encoded by the DNA sequence. “Substantially similar” alsorefers to nucleic acid fragments wherein changes in one or morenucleotide bases does not affect the ability of the nucleic acidfragment to mediate alteration of gene expression by antisense orco-suppression technology. “Substantially similar” also refers tomodifications of the nucleic acid fragments of the instant inventionsuch as deletion or insertion of one or more nucleotide bases that donot substantially affect the functional properties of the resultingtranscript. It is therefore understood that the invention encompassesmore than the specific exemplary sequences. Each of the proposedmodifications is well within the routine skill in the art, as isdetermination of retention of biological activity of the encodedproducts.

Moreover, the skilled artisan recognizes that substantially similarsequences encompassed by this invention are also defined by theirability to hybridize, under stringent conditions (0.1×SSC, 0.1% SDS, 65°C. and washed with 2×SSC, 0.1% SDS followed by 0.1×SSC, 0.1% SDS), withthe sequences exemplified herein. Substantially similar nucleic acidfragments of the instant invention are those nucleic acid fragmentswhose DNA sequences are at least 70% identical to the DNA sequence ofthe nucleic acid fragments reported herein. Preferred substantiallynucleic acid fragments of the instant invention are those,nucleic acidfragments whose DNA sequences are at least 80% identical to the DNAsequence of the nucleic acid fragments reported herein. More preferrednucleic acid fragments are at least 90% identical to the DNA sequence ofthe nucleic acid fragments reported herein. Even more preferred arenucleic acid fragments that are at least 95% identical to the DNAsequence of the nucleic acid fragments reported herein.

Two amino acid sequences are “substantially homologous” or“substantially similar” when greater than about 40% of the amino acidsare identical, or greater than 60% are similar (functionally identical).Preferably, the similar or homologous sequences are identified byalignment using, for example, the GCG (Genetics Computer Group, ProgramManual for the GCG Package, Version 7, Madison, Wis.) pileup program.

The term “corresponding to” is used herein to refer to similar orhomologous sequences, whether the exact position is identical ordifferent from the molecule to which the similarity or homology ismeasured. A nucleic acid or amino acid sequence alignment may includespaces. Thus, the term “corresponding to” refers to the sequencesimilarity, and not the numbering of the amino acid residues ornucleotide bases.

A “substantial portion” of an amino acid or nucleotide sequencecomprises enough of the amino acid sequence of a polypeptide or thenucleotide sequence of a gene to putatively identify that polypeptide orgene, either by manual evaluation of the sequence by one skilled in theart, or by computer-automated sequence comparison and identificationusing algorithms such as BLAST (Basic Local Alignment Search Tool;Altschul, S. F., et al., (1993) J. Mol. Biol. 215:403-410; see alsowww.ncbi.nlm.gov/BLAST/). In general, a sequence of ten or morecontiguous amino acids or thirty or more nucleotides is necessary inorder to putatively identify a polypeptide or nucleic acid sequence ashomologous to a known protein or gene. Moreover, with respect tonucleotide sequences, gene specific oligonucleotide probes comprising20-30 contiguous nucleotides may be used in sequence-dependent methodsof gene identification (e.g., Southern hybridization) and isolation(e.g., in situ hybridization of bacterial colonies or bacteriophageplaques). In addition, short oligonucleotides of 12-15 bases may be usedas amplification primers in PCR in order to obtain a particular nucleicacid fragment comprising the primers. Accordingly, a “substantialportion” of a nucleotide sequence comprises enough of the sequence tospecifically identify and/or isolate a nucleic acid fragment comprisingthe sequence.

The term “percent identity”, as known in the art, is a relationshipbetween two or more polypeptide sequences or two or more polynucleotidesequences, as determined by comparing the sequences. In the art,“identity” also means the degree of sequence relatedness betweenpolypeptide or polynucleotide sequences, as the case may be, asdetermined by the match between strings of such sequences. “Identity”and “similarity” can be readily calculated by known methods, includingbut not limited to those described in: Computational Molecular Biology(Lesk, A. M., ed.) Oxford University Press, New York (1988);Biocomputing: Informatics and Genome Projects (Smith, D. W., ed.)Academic Press, New York (1993); Computer Analysis of Sequence Data,Part I (Griffin, A. M., and Griffin, H. G., eds.) Humana Press, NewJersey (1994); Sequence Analysis in Molecular Biology (von Heinje, G.,ed) Academic Press (1987); and Sequence Analysis Primer (Gribskov, M.and Devereux, J., eds.) Stockton Press, New York (1991). Preferredmethods to determine identity are designed to give the best matchbetween the sequences tested. Methods to determine identity andsimilarity are codified in publicly available computer programs.Sequence alignments and percent identity calculations may be performedusing the Megalign program of the LASERGENE bioinformatics computingsuite (DNASTAR Inc., Madison, Wis.). Multiple alignment of the sequencesmay be performed using the Clustal method of alignment (Higgins andSharp (1989) CABIOS. 5:151-153) with the default parameters (GAPPENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwisealignments using the Clustal method may be selected: KTUPLE 1, GAPPENALTY=3, WINDOW=5 and DIAGONALS SAVED=5.

The term “sequence analysis software” refers to any computer algorithmor software program that is useful for the analysis of nucleotide oramino acid sequences. “Sequence analysis software” may be commerciallyavailable or independently developed. Typical sequence analysis softwarewill include but is not limited to the GCG suite of programs (WisconsinPackage Version 9.0, Genetics Computer Group (GCG), Madison, Wis.),BLASTP, BLASTN, BLASTX (Altschul et al., J. Mol. Biol. 215:403-410(1990), and DNASTAR (DNASTAR, Inc. 1228 S. Park St. Madison, Wis. 53715USA). Within the context of this application it will be understood thatwhere sequence analysis software is used for analysis, that the resultsof the analysis will be based on the “default values” of the programreferenced, unless otherwise specified. As used herein “default values”will mean any set of values or parameters which originally load with thesoftware when first initialized.

“Synthetic genes” can be assembled from oligonucleotide building blocksthat are chemically synthesized using procedures known to those skilledin the art. These building blocks are ligated and annealed to form genesegments that are then enzymatically assembled to construct the entiregene. “Chemically synthesized”, as related to a sequence of DNA, meansthat the component nucleotides were assembled in vitro. Manual chemicalsynthesis of DNA may be accomplished using well established procedures,or automated chemical synthesis can be performed using one of a numberof commercially available machines. Accordingly, the genes can betailored for optimal gene expression based on optimization of nucleotidesequence to reflect the codon bias of the host cell. The skilled artisanappreciates the likelihood of successful gene expression if codon usageis biased towards those codons favored by the host. Determination ofpreferred codons can be based on a survey of genes derived from the hostcell where sequence information is available.

Gene Expression Modulation System of the Invention

Applicants have now shown that separating the transactivation and DNAbinding domains by placing them on two different proteins results ingreatly reduced background activity in the absence of a ligand andsignificantly increased activity over background in the presence of aligand. Applicants' improved gene expression system comprises twochimeric gene expression; the first encoding a DNA binding domain fusedto a nuclear receptor polypeptide and the second encoding atransactivation domain fused to a nuclear receptor polypeptide. Theinteraction of the first protein with the second protein effectivelytethers the DNA binding domain to the transactivation domain. Since theDNA binding and transactivation domains reside on two differentmolecules, the background activity in the absence of ligand is greatlyreduced.

In general, the inducible gene expression modulation system of theinvention comprises a) a first chimeric gene that is capable of beingexpressed in a host cell comprising a polynucleotide sequence thatencodes a first hybrid polypeptide comprising i) a DNA-binding domainthat recognizes a response element associated with a gene whoseexpression is to be modulated; and ii) a ligand binding domaincomprising the ligand binding domain from a nuclear receptor; and b) asecond chimeric gene that is capable of being expressed in the host cellcomprising a polynucleotide sequence that encodes a second hybridpolypeptide comprising: i) a transactivation domain; and a ligandbinding domain comprising the ligand binding domain from a nuclearreceptor other than ultraspiracle (USP); wherein the transactivationdomain are from other than EcR, RXR, or USP; and wherein the ligandbinding domains from the first hybrid polypeptide and the second hybridpolypeptide are different and dimerize.

This two-hybrid system exploits the ability of a pair of interactingproteins to bring the transcription activation domain into a morefavorable position relative to the DNA binding domain such that when theDNA binding domain binds to the DNA binding site on the gene, thetransactivation domain more effectively activates the promoter (see, forexample, U.S. Pat. No. 5,283,173). This two-hybrid system is asignificantly improved inducible gene expression modulation systemcompared to the two systems disclosed in International PatentApplications PCT/US97/05330 and PCT/US98/14215.

The ecdysone receptor-based gene expression modulation system of theinvention may be either heterodimeric and homodimeric. A functional EcRcomplex generally refers to a heterodimeric protein complex consistingof two members of the steroid receptor family, an ecdysone receptorprotein obtained from various insects, and an ultraspiracle (USP)protein or the vertebrate homolog of USP, retinoid X receptor protein(see Yao, et al. (1993) Nature 366, 476-479; Yao, et al., (1992) Cell71, 63-72). However, the complex may also be a homodimer as detailedbelow. The functional ecdysteroid receptor complex may also includeadditional protein(s) such as immunophilins. Additional members of thesteroid receptor family of proteins, known as transcriptional factors(such as DHR38 or betaFTZ-1), may also be ligand dependent orindependent partners for EcR, USP, and/or RXR. Additionally, othercofactors may be required such as proteins generally known ascoactivators (also termed adapters or mediators). These proteins do notbind sequence-specifically to DNA and are not involved in basaltranscription. They may exert their effect on transcription activationthrough various mechanisms, including stimulation of DNA-binding ofactivators, by affecting chromatin structure, or by mediatingactivator-initiation complex interactions. Examples of such coactivatorsinclude RIP140, TIF1, RAP46/Bag-1, ARA70, SRC-1/NCoA-1,TIF2/GRIP/NCoA-2, ACTR/AIB1/RAC3/pCIP as well as the promiscuouscoactivator C response element B binding protein, CBP/p300 (for reviewsee Glass et al, Curr. Opin. Cell Biol. 9:222-232, 1997). Also, proteincofactors generally known as corepressors (also known as repressors,silencers, or silencing mediators) may be required to effectivelyinhibit transcriptional activation in the absence of ligand. Thesecorepressors may interact with the unliganded ecdysone receptor tosilence the activity at the response element. Current evidence suggeststhat binding of ligand changes the conformation of the receptor, whichresults in release of the corepressor and recruitment of the abovedescribed coactivators, thereby abolishing their silencing activity.Examples of corepressors include N-CoR and SMRT (for review, see Horwitzet al. Mol Endocrinol. 10: 1167-1177, 1996). These cofactors may eitherbe endogenous within the cell or organism, or may be added exogenouslyas transgenes to be expressed in either a regulated or unregulatedfashion. Homodimer complexes of the ecdysone receptor protein, USP, orRXR may also be functional under some circumstances.

The ecdysone receptor complex typically includes proteins which aremembers of the nuclear receptor superfamily wherein all members arecharacterized by the presence of an amino-terminal transactivationdomain, a DNA binding domain (“DBD”), and a ligand binding domain(“LBD”) separated from the DBD by a hinge region. As used herein, theterm “DNA binding domain” comprises a minimal peptide sequence of a DNAbinding protein, up to the entire length of a DNA binding protein, solong as the DNA binding domain functions to associate with a particularresponse element. Members of the nuclear receptor superfamily are alsocharacterized by the presence of four or five domains: A/B, C, D, E, andin some members F (see Evans, Science 240:889-895 (1988)). The “A/B”domain corresponds to the transactivation domain, “C” corresponds to theDNA binding domain, “D” corresponds to the binge region, and “E”corresponds to the ligand binding domain. Some members of the family mayalso have another transactivation domain on the carboxy-terminal side ofthe LBD corresponding to “F”.

The DBD is characterized by the presence of two cysteine zinc fingersbetween which are two amino acid motifs, the P-box and the D-box, whichconfer specificity for ecdysone response elements. These domains may beeither native, modified, or chimeras of different domains ofheterologous receptor proteins. This EcR receptor, like a subset of thesteroid receptor family, also possesses less well defined regionsresponsible for heterodimerization properties. Because the domains ofEcR, USP, and RXR are modular in nature, the LBD, DBD, andtransactivation domains may be interchanged.

Gene switch systems are known that incorporate components from theecdysone receptor complex. However, in these known systems, whenever EcRis used it is associated with native or modified DNA binding domains andtransactivation domains on the same molecule. USP or RXR are typicallyused as silent partners. We have now shown that when DNA binding domainsand transactivation domains are on the same molecule the backgroundactivity in the absence of ligand is high and that such activity isdramatically reduced when DNA binding domains and transactivationdomains are on different molecules, that is, on each of two partners ofa heterodimeric or homodimeric complex. This two-hybrid system alsoprovides improved sensitivity to non-steroidal ligands for example,diacylhydrazines, when compared to steroidal ligands for example,ponasterone A (“PonA”) or muristerone A (“MurA”). That is, when comparedto steroids, the non-steroidal ligands provide higher activity at alower concentration. In addition, since transactivation based on EcRgene switches is often cell-line dependent, it is easier to tailorswitching system to obtain maximum transactivation capability for eachapplication. Furthermore, this two-hybrid system avoids some sideeffects due to overexpression of RXR that often occur when unmodifiedRXR is used as a switching partner. In this two-hybrid system, nativeDNA binding and transactivation domains of EcR or RXR are eliminated. Asa result, these chimeric molecules have less chance of interacting withother steroid hormone receptors present in the cell resulting in reducedside effects.

Specifically, Applicants' invention relates to a gene expressionmodulation system comprising: a) a first gene expression cassette thatis capable of being expressed in a host cell, wherein the first geneexpression cassette comprises a polynucleotide that encodes a firstpolypeptide comprising i) a DNA-binding domain that recognizes aresponse element associated with a gene whose expression is to bemodulated; and a ligand binding domain comprising a ligand bindingdomain from a nuclear receptor; and b) a second gene expression cassettethat is capable of being expressed in the host cell, wherein the secondgene expression cassette comprises a polynucleotide sequence thatencodes a second polypeptide comprising i) a transactivation domain; andii) a ligand binding domain comprising a ligand binding domain from anuclear receptor other than ultraspiracle (USP); wherein the DNA bindingdomain and the transactivation domain are from other than EcR, RXR, orUSP; wherein the ligand binding domains from the first polypeptide andthe second polypeptide are different and dimerize.

The present invention also relates to a gene expression modulationsystem according to the present invention further comprising c) a thirdgene expression cassette comprising: i) the response element to whichthe DNA-binding domain of the first polypeptide binds; a promoter thatis activated by the transactivation domain of the second polypeptide;and the gene whose expression is to be modulated.

In a specific embodiment, the gene whose expression is to be modulatedis a homologous gene with respect to the host cell. In another specificembodiment, the gene whose expression is to be modulated is aheterologous gene with respect to the host cell.

In a specific embodiment, the ligand binding domain of the firstpolypeptide comprises an ecdysone receptor ligand binding domain.

In another specific embodiment, the ligand binding domain of the firstpolypeptide comprises a retinoid X receptor ligand binding domain.

In a specific embodiment, the ligand binding domain of the secondpolypeptide comprises an ecdysone receptor ligand binding domain.

In another specific embodiment, the ligand binding domain of the secondpolypeptide comprises a retinoid X receptor ligand binding domain.

In a preferred embodiment, the ligand binding domain of the firstpolypeptide comprises an ecdysone receptor ligand binding domain, andthe ligand binding domain of the second polypeptide comprises a retinoidX receptor ligand binding domain.

In another preferred embodiment, the ligand binding domain of the firstpolypeptide is from a retinoid X receptor polypeptide, and the ligandbinding domain of the second polypeptide is from an ecdysone receptorpolypeptide.

Preferably, the ligand binding domain is an EcR or RXR relatedsteroid/thyroid hormone nuclear receptor family member ligand bindingdomain, or analogs, combinations, or modifications thereof. Morepreferably, the LBD is from EcR or RXR. Even more preferably, the LBD isfrom a truncated EcR or RXR. A truncation mutation may be made by anymethod used in the art, including but not limited to restrictionendonuclease digestion/deletion, PCR-mediated/oligonucleotide-directeddeletion, chemical mutagenesis, UV strand breakage, and the like.

Preferably, the EcR is an insect EcR selected from the group consistingof a Lepidopteran EcR, a Dipteran EcR, an Arthropod EcR, a HomopteranEcR and a Hemipteran EcR. More preferably, the EcR for use is a sprucebudworm Choristoneura fumiferana EcR (“CfEcR”), a Tenebrio molitor EcR(“TmEcR”), a Manduca sexta EcR (“MsEcR”), a Heliothies virescens EcR(“HvEcR”), a silk moth Bombyx mori EcR (“BmEcR”), a fruit fly Drosophilamelanogaster EcR (“DmEcR”), a mosquito Aedes aegypti EcR (“AaEcR”), ablowfly Lucilia capitata EcR (“LcEcR”), a Mediterranean fruit flyCeratitis capitata EcR (“CcEcR”), a locust Locusta migratoria EcR(“LmEcR”), an aphid Myzus persicae EcR (“MpEcR”), a fiddler crab Ucapugilator EcR (“UpEcR”), or an ixodid tick Amblyomma americanum EcR(“AmaEcR”). Even more preferably, the LBD is from spruce budworm(Choristoneura fumiferana) EcR (“CfEcR”) or fruit fly Drosophilamelanogaster EcR (“DmEcR”).

Preferably, the LBD is from a truncated insect EcR. The insect EcRpolypeptide truncation comprises a deletion of at least 1, 2, 3, 4, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95,100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165,170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 25,240, 245, 250, 255, 260, or 265 amino acids. More preferably, the insectEcR polypeptide truncation comprises a deletion of at least a partialpolypeptide domain. Even more preferably, the insect EcR polypeptidetruncation comprises a deletion of at least an entire polypeptidedomain. In a specific embodiment, the insect EcR polypeptide truncationcomprises a deletion of at least an A/B-domain deletion, a C-domaindeletion, a D-domain deletion, an E-domain deletion, an F-domaindeletion, an A/B/C-domains deletion, an A/B/1/2-C-domains deletion, anA/B/C/D-domains deletion, an A/B/C/D/F-domains deletion, anA/B/F-domains, and an A/B/C/F-domains deletion. A combination of severalcomplete and/or partial domain deletions may also be performed.

In a preferred embodiment, the ecdysone receptor ligand binding domainis encoded by a polynucleotide comprising a nucleic acid sequenceselected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ IDNO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ IDNO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

In another preferred embodiment, the ecdysone receptor ligand bindingdomain comprises a polypeptide sequence selected from the groupconsisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO:14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ IDNO: 19, and SEQ ID NO: 20.

Preferably, the RXR polypeptide is a mouse Mus musculus RXR (“MmRXR”) ora human Homo sapiens RXR (“HsRXR”). The RXR polypeptide may be anRXR_(α), RXR_(β), or RXR isoform.

Preferably, the LBD is from a truncated RXR. The RXR polypeptidetruncation comprises a deletion of at least 1, 2, 3, 4, 5, 10, 15, 20,25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105,110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175,180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245,250, 255, 260, or 265 amino acids. More preferably, the RXR polypeptidetruncation comprises a deletion of at least a partial polypeptidedomain. Even more preferably, the RXR polypeptide truncation comprises adeletion of at least an entire polypeptide domain. In a specificembodiment, the RXR polypeptide truncation comprises a deletion of atleast an A/B-domain deletion, a C-domain deletion, a D-domain deletion,an E-domain deletion, an F-domain deletion, an A/B/C-domains deletion,an A/B/1/2-C-domains deletion, an A/B/C/D-domains deletion, anA/B/C/D/F-domains deletion, an A/B/F-domains, and an A/B/C/F-domainsdeletion. A combination of several complete and/or partial domaindeletions may also be performed.

In a preferred embodiment, the retinoid X receptor ligand binding domainis encoded by a polynucleotide comprising a nucleic acid sequenceselected from the group consisting of SEQ ID NO: 21, SEQ ID NO: 22, SEQID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27,SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30.

In another preferred embodiment, the retinoid X receptor ligand bindingdomain comprises a polypeptide sequence selected from the groupconsisting of SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO:34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ IDNO: 39, and SEQ ID NO: 40.

For purposes of this invention EcR and RXR also include synthetic andchimeric EcR and RXR and their homologs.

The DNA binding domain can be any DNA binding domain with a knownresponse element, including synthetic and chimeric DNA binding domains,or analogs, combinations, or modifications thereof. Preferably, the DBDis a GAL4 DBD, a LexA DBD, a transcription factor DBD, a steroid/thyroidhormone nuclear receptor superfamily member DBD, a bacterial LacZ DBD,or a yeast put DBD. More preferably, the DBD is a GAL4 DBD [SEQ ID NO:41 (polynucleotide) or SEQ ID NO: 42 (polypeptide)] or a LexA DBD [(SEQID NO: 43 (polynucleotide) or SEQ ID NO: 44 (polypeptide)].

The transactivation domain (abbreviated “AD” or “TA”) may be anysteroid/thyroid hormone nuclear receptor AD, synthetic or chimeric AD,polyglutamine AD, basic or acidic amino acid AD, a VP16 AD, a GAL4 AD,an NF-κB AD, a BP64 AD, or an analog, combination, or modificationthereof. Preferably, the AD is a synthetic or chimeric AD, or isobtained from a VP16, GAL4, or NF-κB. Most preferably, the AD is a VP16AD [SEQ ID NO: 45 (polynucleotide) or SEQ ID NO: 46 (polypeptide)].

The response element (“RE”) may be any response element with a known DNAbinding domain, or an analog, combination, or modification thereof.Preferably, the RE is an RE from GAL4 (“GAL4RE”), LexA, asteroid/thyroid hormone nuclear receptor RE, or a synthetic RE thatrecognizes a synthetic DNA binding domain. More preferably, the RE is aGAL4RE comprising a polynucleotide sequence of SEQ ID NO: 47 or a LexA8X operon comprising a polynucleotide sequence of SEQ ID NO: 48.Preferably, the first hybrid protein is substantially free of atransactivation domain and the second hybrid protein is substantiallyfree of a DNA binding domain. For purposes of this invention,“substantially free” means that the protein in question does not containa sufficient sequence of the domain in question to provide activation orbinding activity.

The ligands for use in the present invention as described below, whencombined with the ligand binding domain of an EcR USP, RXR, or anotherpolypeptide which in turn are bound to the response element linked to agene, provide the means for external temporal regulation of expressionof the gene. The binding mechanism or the order in which the variouscomponents of this invention bind to each other, that is, ligand toreceptor, first polypeptide to response element, second polypeptide topromoter, etc., is not critical. Binding of the ligand to the ligandbinding domains of an EcR, USP, RXR, or another protein, enablesexpression or suppression of the gene. This mechanism does not excludethe potential for ligand binding to EcR, USP, or RXR, and the resultingformation of active homodimer complexes (e.g. EcR+EcR or USP+USP).Preferably, one or more of the receptor domains can be varied producinga chimeric gene switch. Typically, one or more of the three domains,DBD, LBD, and transactivation domain, may be chosen from a sourcedifferent than the source of the other domains so that the chimericgenes and the resulting hybrid proteins are optimized in the chosen hostcell or organism for transactivating activity, complementary binding ofthe ligand, and recognition of a specific response element. In addition,the response element itself can be modified or substituted with responseelements for other DNA binding protein domains such as the GAL-4 proteinfrom yeast (see Sadowski, et al. (1988) Nature, 335:563-564) or LexAprotein from E. coli (see Brent and Ptashne (1985), Cell, 43:729-736),or synthetic response elements specific for targeted interactions withproteins designed, modified, and selected for such specific interactions(see, for example, Kim, et al. (1997), Proc. Natl. Acad. Sci., USA,94:3616-3620) to accommodate chimeric receptors. Another advantage ofchimeric systems is that they allow choice of a promoter used to drivethe gene expression according to a desired end result. Such doublecontrol can be particularly important in areas of gene therapy,especially when cytotoxic proteins are produced, because both the timingof expression as well as the cells wherein expression occurs can becontrolled. When genes, operatively linked to a suitable promoter, areintroduced into the cells of the subject, expression of the exogenousgenes is controlled by the presence of the system of this invention.Promoters may be constitutively or inducibly regulated or may betissue-specific (that is, expressed only in a particular type of cells)or specific to certain developmental stages of the organism

Gene Expression Cassettes of the Invention

The novel ecdysone receptor-based inducible gene expression system ofthe invention comprises a novel gene expression cassette that is capableof being expressed j a host cell, wherein the gene expression cassettecomprises a polynucleotide encoding a hybrid polypeptide. Thus,Applicants' invention also provides novel gene expression cassettes foruse in the gene expression system of the invention.

Specifically, the present invention provides a gene expression cassettecomprising a polynucleotide encoding a hybrid polypeptide. The hybridpolypeptide comprises either 1) a DNA-binding domain that recognizes aresponse element and a ligand binding domain of a nuclear receptor or 2)a transactivation domain and a ligand binding domain of a nuclearreceptor, wherein the transactivation domain is from a nuclear receptorother than an EcR, an RXR, or a USP.

In a specific embodiment, the gene expression cassette encodes a hybridpolypeptide comprising a DNA-binding domain that recognizes a responseelement and an ecdysone receptor ligand binding domain, wherein the DNAbinding domain is from a nuclear receptor other than an ecdysonereceptor.

In another specific embodiment, the gene expression cassette encodes ahybrid polypeptide comprising a DNA-binding domain that recognizes aresponse element and a retinoid X receptor ligand binding domain,wherein the DNA binding domain is from a nuclear receptor other than aretinoid X receptor.

The DNA binding domain can be any DNA binding domain with a knownresponse element, including synthetic, and chimeric DNA binding domains,or analogs, combinations, or modifications thereof. Preferably, the DBDis a GAL4 DBD, a LexA DBD, a transcription factor DBD, a steroid/thyroidhormone nuclear receptor superfamily member DBD, a bacterial LacZ DBD,or a yeast put DBD. More preferably, the DBD is a GAL4 DBD [SEQ ID NO:41 (polynucleotide) or SEQ ID NO: 42 (polypeptide)] or a LexA DBD [(SEQID NO: 43 (polynucleotide) or SEQ ID NO: 44 (polypeptide)].

In another specific embodiment, the gene expression cassette encodes ahybrid polypeptide comprising a transactivation domain and an ecdysonereceptor ligand binding domain, wherein the transactivation domain isfrom a nuclear receptor other than an ecdysone receptor.

In another specific embodiment, the gene expression cassette encodes ahybrid polypeptide comprising a transactivation domain and a retinoid Xreceptor ligand binding domain, wherein the transactivation domain isfrom a nuclear receptor other than a retinoid X receptor.

The transactivation domain (abbreviated “AD” or “TA”) may be anysteroid/thyroid hormone nuclear receptor AD, synthetic or chimeric AD,polyglutamine AD, basic or acidic amino acid AD, a VP16 AD, a GAL4 AD,an NF-κB AD, a BP64 AD, or an analog, combination, or modificationthereof. Preferably, the AD is a synthetic or chimeric AD, or isobtained from a VP16, GAL4, or NF-κB. Most preferably, the AD is a VP16AD [SEQ ID NO: 45 (polynucleotide) or SEQ ID NO: 46 (polypeptide)].

Preferably, the ligand binding domain is an EcR or RXR relatedsteroid/thyroid hormone nuclear receptor family member ligand bindingdomain, or analogs, combinations, or modifications thereof. Morepreferably, the LBD is from EcR or RXR. Even more preferably, the LBD isfrom a truncated EcR or RXR.

Preferably, the EcR is an insect EcR selected from the group consistingof a Lepidopteran EcR, a Dipteran EcR, an Arthropod EcR, a HomopteranEcR and a Hemipteran EcR. More preferably, the EcR for use is a sprucebudworm Choristoneura fumiferana EcR (“CfEcR”), a Tenebrio molitor EcR(“TmEcR”), a Manduca sexta EcR (“MsEcR”), a Heliothies virescens EcR(“HvEcR”), a silk moth Bombyx mori EcR (“BmEcR”), a fruit fly Drosophilamelanogaster EcR (“DmEcR”), a mosquito Aedes aegypti EcR (“AaEcR”), ablowfly Lucilia capitata EcR (“LcEcR”), a Mediterranean fruit flyCeratitis capitata EcR (“CcEcR”), a locust Locusta migratoria EcR(“LmEcR”), an aphid Myzus persicae EcR (“MpEcR”), a fiddler crab Ucapugilator EcR (“UpEcR”), or an ixodid tick Amblyomma americanum EcR(“AmaEcR”). Even more preferably, the LBD is from spruce budworm(Choristoneura fumiferana) EcR (“CfEcR”) or fruit fly Drosophilamelanogaster EcR (“DmEcR”).

Preferably, the LBD is from a truncated insect EcR. The insect EcRpolypeptide truncation comprises a deletion of at least 1, 2, 3, 4, 5,10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95,100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165,170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235,240, 245, 250, 255, 260, or 265 amino acids. More preferably, the insectEcR polypeptide truncation comprises a deletion of at least a partialpolypeptide domain. Even more preferably, the insect EcR polypeptidetruncation comprises a deletion of at least an entire polypeptidedomain. In a specific embodiment, the insect EcR polypeptide truncationcomprises a deletion of at least an A/B-domain deletion, a C-domaindeletion, a D-domain deletion, an E-domain deletion, an F-domaindeletion, an A/B/C-domains deletion, an A/B/1/2-C-domains deletion, anA/B/C/D-domains deletion, an A/B/C/D/F-domains deletion, anA/B/F-domains, and an A/B/C/F-domains deletion. A combination of severalcomplete and/or partial domain deletions may also be performed.

In a preferred embodiment, the ecdysone receptor ligand binding domainis encoded by a polynucleotide comprising a nucleic acid sequenceselected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ IDNO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ IDNO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

In another preferred embodiment, the ecdysone receptor ligand bindingdomain comprises an amino acid sequence selected from the groupconsisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO:14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ IDNO: 19, and SEQ ID NO: 20.

Preferably, the RXR polypeptide is a mouse Mus musculus RXR (“MmRXR”) ora human Homo sapiens RXR (“HsRXR”). The RXR polypeptide may be anRXR_(α), RXR_(β), or RXR_(γ) isoform.

Preferably, the LBD is from a truncated RXR. The RXR polypeptidetruncation comprises a deletion of at least 1, 2, 3, 4, 5, 10, 15, 20,25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105,110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175,180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245,250, 255, 260, or 265 amino acids. More preferably, the RXR polypeptidetruncation comprises a deletion of at least a partial polypeptidedomain. Even more preferably, the RXR polypeptide truncation comprises adeletion of at least an entire polypeptide domain. In a specificembodiment, the RXR polypeptide truncation comprises a deletion of atleast an A/B-domain deletion, a C-domain deletion, a D-domain deletion,an E-domain deletion, an F-domain deletion, an A/B/C-domains deletion,an A/B/1/2-C-domains deletion, an A/B/C/D-domains deletion, anA/B/C/D/F-domains deletion, an A/B/F-domains, and an A/B/C/F-domainsdeletion. A combination of several complete and/or partial domaindeletions may also be performed.

In a preferred embodiment, the retinoid X receptor ligand binding domainis encoded by a polynucleotide comprising a nucleic acid sequenceselected from the group consisting of SEQ ID NO: 21, SEQ ID NO: 22, SEQID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27,SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30.

In another preferred embodiment, the retinoid X receptor ligand bindingdomain comprises an amino acid sequence selected from the groupconsisting of SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO:34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ IDNO: 39, and SEQ ID NO: 40.

In a preferred embodiment, the gene expression cassette encodes a hybridpolypeptide comprising a DNA-binding domain encoded by a polynucleotidecomprising a nucleic acid sequence selected from the group consisting ofa GALA DBD (SEQ IL NO: 41) or a LexA DBD (SEQ ID NO: 43) and an ecdysonereceptor ligand binding domain encoded by a polynucleotide comprising anucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6,SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

In another preferred embodiment, the gene expression cassette encodes ahybrid polypeptide comprising a DNA-binding domain comprising apolypeptide sequence selected from the group consisting of a GAL4 DBD(SEQ ID NO: 42) or a LexA DBD (SEQ ID NO: 44) and an ecdysone receptorligand binding domain comprising an amino acid sequence selected fromthe group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18,SEQ ID NO: 19, and SEQ ID NO: 20.

In another preferred embodiment, the gene expression cassette encodes ahybrid polypeptide comprising a DNA-binding domain encoded by apolynucleotide comprising a nucleic acid sequence selected from thegroup consisting of a GAL4 DBD (SEQ ID NO: 41) or a LexA DBD (SEQ ID NO:43) and a retinoid X receptor ligand binding domain encoded by apolynucleotide comprising a nucleic acid sequence selected from thegroup consisting of SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ IDNO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQID NO: 29, and SEQ ID NO: 30.

In another preferred embodiment, the gene expression cassette encodes ahybrid polypeptide comprising a DNA-binding domain comprising apolypeptide sequence selected from the group consisting of a GAL4 DBD(SEQ ID NO: 42) or a LexA DBD (SEQ ID NO: 44) and a retinoid X receptorligand binding domain comprising an amino acid sequence selected fromthe group consisting of SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38,SEQ ID NO: 39, and SEQ ID NO: 40.

In another preferred embodiment, the gene expression cassette encodes ahybrid polypeptide comprising a transactivation domain encoded by apolynucleotide comprising a nucleic acid sequence of SEQ ID NO: 45 andan ecdysone receptor ligand binding domain encoded by a polynucleotidecomprising a nucleic acid sequence selected from the group consisting ofSEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5,SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO:10.

In another preferred embodiment, the gene expression cassette encodes ahybrid polypeptide comprising a transactivation domain comprising apolypeptide sequence of SEQ ID NO: 46 and an ecdysone receptor ligandbinding domain comprising a polypeptide sequence selected from the groupconsisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO:14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ IDNO: 19, and SEQ ID NO: 20.

In another preferred embodiment, the gene expression cassette encodes ahybrid polypeptide comprising a transactivation domain encoded by apolynucleotide comprising a nucleic acid sequence of SEQ ID NO: 45 and aretinoid X receptor ligand binding domain encoded by a polynucleotidecomprising a nucleic acid sequence selected from the group consisting ofSEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO:25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQID NO: 30.

In another preferred embodiment, the gene expression cassette encodes ahybrid polypeptide comprising a transactivation domain comprising apolypeptide sequence of SEQ ID NO: 46 and a retinoid X receptor ligandbinding domain comprising an amino acid sequence selected from the groupconsisting of SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO:34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ IDNO: 39, and SEQ ID NO: 40.

For purposes of this invention EcR and RXR also include synthetic andchimeric EcR and RXR and their homologs.

Polynucleotides of the Invention

The novel ecdysone receptor-based inducible gene expression system ofthe invention comprises a gene expression cassette comprising apolynucleotide that encodes a truncated EcR or RXR polypeptidecomprising a truncation mutation and is useful in methods of modulatingthe expression of a gene within a host cell.

Thus, the present invention also relates to a polynucleotide thatencodes an EcR or RXR polypeptide comprising a truncation mutation.Specifically, the present invention relates to an isolatedpolynucleotide encoding an EcR or RXR polypeptide comprising atruncation mutation that affects ligand binding activity or ligandsensitivity.

Preferably, the truncation mutation results in a polynucleotide thatencodes a truncated EcR polypeptide or a truncated RXR polypeptidecomprising a deletion of at least 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35,40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120,125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190,195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, or265 amino acids. More preferably, the EcR or RXR polypeptide truncationcomprises a deletion of at least a partial polypeptide domain. Even morepreferably, the EcR or RXR polypeptide truncation comprises a deletionof at least an entire polypeptide domain. In a specific embodiment, theEcR or RXR polypeptide truncation comprises a deletion of at least anA/B-domain deletion, a C-domain deletion, a D-domain deletion, anE-domain deletion, an F-domain deletion, an A/B/C-domains deletion, anA/B/1/2-C-domains deletion, an A/B/C/D-domains deletion, anA/B/C/D/F-domains deletion, an A/B/F-domains, and an A/B/C/F-domainsdeletion. A combination of several complete and/or partial domaindeletions may also be performed.

In a specific embodiment, the EcR polynucleotide according to theinvention comprises a polynucleotide sequence selected from the groupconsisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4,SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9,and SEQ ID NO: 10. In a specific embodiment, the polynucleotideaccording to the invention encodes a ecdysone receptor polypeptidecomprising an amino acid sequence selected from the group consisting ofSEQ ID NO: 11 (CfEcR-CDEF), SEQ ID NO: 12 (CfEcR-1/2CDEF, whichcomprises the last 33 carboxy-terminal amino acids of C domain), SEQ IDNO: 13 (CfEcR-DEF), SEQ ID NO: 14 (CfEcR-EF), SEQ ID NO: 15 (CfEcR-DE),SEQ ID NO: 16 (DmEcR-CDEF), SEQ ID NO: 17 (DmEcR-1/2CDEF), SEQ ID NO: 18(DmEcR-DEF), SEQ ID NO: 19 (DmEcR-EF), and SEQ ID NO: 20 (DmEcR-DE).

In another specific embodiment, the RXR polynucleotide according to theinvention comprises a polynucleotide sequence selected from the groupconsisting of SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO:24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ IDNO: 29, and SEQ ID NO: 30. In another specific embodiment, thepolynucleotide according to the invention encodes a truncated RXRpolypeptide comprising an amino acid sequence consisting of SEQ ID NO:31 (MmRXR-CDEF), SEQ ID NO: 32 (MmRXR-DEF), SEQ ID NO: 33 (MmRXR-EF),SEQ ID NO: 34 (MmRXR-truncatedEF), SEQ ID NO: 35 (MmRXR-E), SEQ ID NO:36 (HsRXR-CDEF), SEQ ID NO: 37 (HsRXR-DEF), SEQ ID NO: 38 (HsRXR-EF),SEQ ID NO: 39 (HsRXR-truncated EF), and SEQ ID NO: 40 (HsRXR-E).

In particular, the present invention relates to an isolatedpolynucleotide encoding an EcR or RXR polypeptide comprising atruncation mutation, wherein the mutation reduces ligand bindingactivity or ligand sensitivity of the EcR or RXR polypeptide. In aspecific embodiment, the present invention relates to an isolatedpolynucleotide encoding an EcR or RXR polypeptide comprising atruncation mutation that reduces steroid binding activity or steroidsensitivity of the EcR or RXR polypeptide. In a preferred embodiment,the present invention relates to an isolated polynucleotide encoding anEcR polypeptide comprising a truncation mutation that reduces steroidbinding activity or steroid sensitivity of the EcR polypeptide, whereinthe polynucleotide comprises a nucleic acid sequence of SEQ ID NO: 3(CfEcR-DEF), SEQ ID NO: 4 (CfEcR-EF), SEQ ID NO: 8 (DmEcR-DEF), or SEQID NO: 9 (DmEcR-EF). In another specific embodiment, the presentinvention relates to an isolated polynucleotide encoding an EcR or RXRpolypeptide comprising a truncation mutation that reduces non-steroidbinding activity or non-steroid sensitivity of the EcR or RXRpolypeptide. In a preferred embodiment, the present invention relates toan isolated polynucleotide encoding an EcR polypeptide comprising atruncation mutation that reduces non-steroid binding activity ornon-steroid sensitivity of the EcR polypeptide, wherein thepolynucleotide comprises a nucleic acid sequence of SEQ ID NO: 4(CfEcR-EF) or SEQ ID NO: 9 (DmEcR-EF).

The present invention also relates to an isolated polynucleotideencoding an EcR or RXR polypeptide comprising a truncation mutation,wherein the mutation enhances ligand binding activity or ligandsensitivity of the EcR or RXR polypeptide. In a specific embodiment, thepresent invention relates to an isolated polynucleotide encoding an EcRor RXR polypeptide comprising a truncation mutation that enhancessteroid binding activity or steroid sensitivity of the EcR or RXRpolypeptide. In another specific embodiment, the present inventionrelates to an isolated polynucleotide encoding an EcR or RXR polypeptidecomprising a truncation mutation that enhances non-steroid bindingactivity or non-steroid sensitivity of the EcR or RXR polypeptide. In apreferred embodiment, the present invention relates to an isolatedpolynucleotide encoding an EcR polypeptide comprising a truncationmutation that enhances non-steroid binding activity or non-steroidsensitivity of the EcR polypeptide, wherein the polynucleotide comprisesa nucleic acid sequence of SEQ ID NO: 3 (CfEcR-DEF) or SEQ NO: 8(DmEcR-DEF).

The present invention also relates to an isolated polynucleotideencoding a retinoid X receptor polypeptide comprising a truncationmutation that increases ligand sensitivity of a heterodimer comprisingthe mutated retinoid X receptor polypeptide and a dimerization partner.Preferably, the isolated polynucleotide encoding a retinoid X receptorpolypeptide comprising a truncation mutation that increases ligandsensitivity of a heterodimer comprises a polynucleotide sequenceselected from the group consisting of SEQ ID NO: 23 (MmRXR-EF), SEQ IDNO: 24 (MmRXR-truncatedEF), SEQ ID NO: 28 (HsRXR-EF), or SEQ ID NO: 29(HsRXR-truncated EF). In a specific embodiment, the dimerization partneris an ecdysone receptor polypeptide. Preferably, the dimerizationpartner is a truncated EcR polypeptide. More preferably, thedimerization partner is an EcR polypeptide in which domains A/B/C havebeen deleted. Even more preferably, the dimerization partner is an EcRpolypeptide comprising an amino acid sequence of SEQ ID NO: 13(CfEcR-DEF) or SEQ ID NO: 18 (DmEcR-DEF).

Polypeptides of the Invention

The novel ecdysone receptor-based inducible gene expression system ofthe invention comprises a polynucleotide that encodes a truncated EcR orRXR polypeptide and is useful in methods of modulating the expression ofa gene within a host cell. Thus, the present invention also relates toan isolated truncated EcR or RXR polypeptide encoded by a polynucleotideor a gene expression cassette according to the invention. Specifically,the present invention relates to an isolated truncated EcR or RXRpolypeptide comprising a truncation mutation that affects ligand bindingactivity or ligand sensitivity encoded by a polynucleotide according tothe invention.

The present invention also relates to an isolated truncated EcR or RXRpolypeptide comprising a truncation mutation. Specifically, the presentinvention relates to an isolated EcR or RXR polypeptide comprising atruncation mutation that affects ligand binding activity or ligandsensitivity.

Preferably, the truncation mutation results in a truncated EcRpolypeptide or a truncated RXR polypeptide comprising a deletion of atleast 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70,75, 80, 85, 90, 95, 100, 105, 110, 11.5, 120, 125, 130, 135, 140, 145,150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215,220, 225, 230, 235, 240, 245, 250, 255, 260, or 265 amino acids. Morepreferably, the EcR or RXR polypeptide truncation comprises a deletionof at least a partial polypeptide domain. Even more preferably, the EcRor RXR polypeptide truncation comprises a deletion of at least an entirepolypeptide domain. In a specific embodiment, the EcR or RXR polypeptidetruncation comprises a deletion of at least an A/B-domain deletion, aC-domain deletion, a D-domain deletion, an E-domain deletion, anF-domain deletion, an A/B/C-domains deletion, an A/B/1/2-C-domainsdeletion, an A/B/C/D-domains deletion, an A/B/C/D/F-domains deletion, anA/B/F-domains, and an A/B/C/F-domains deletion. A combination of severalcomplete and/or partial domain deletions may also be performed.

In a preferred embodiment, the isolated truncated ecdysone receptorpolypeptide is encoded by a polynucleotide comprising a polynucleotidesequence selected from the group consisting of SEQ ID NO: 1(CfEcR-CDEF), SEQ ID NO: 2 (CfEcR-1/2CDEF), SEQ ID NO: 3 (CfEcR-DEF),SEQ ID NO: 4 (CfEcR-EF), SEQ ID NO: 5 (CfEcR-DE), SEQ ID NO: 6(DmEcR-CDEF), SEQ ID NO: 7 (DmEcR-1/2CDEF), SEQ ID NO: 8 (DmEcR-DEF),SEQ ID NO: 9 (DmEcR-EF), and SEQ ID NO: 10 (DmEcR-DE). In anotherpreferred embodiment, the isolated truncated ecdysone receptorpolypeptide comprises an amino acid sequence selected from the groupconsisting of SEQ ID NO: 11 (CfEcR-CDEF), SEQ ID NO: 12 (CfEcR-1/2CDEF),SEQ ID NO: 13 (CfEcR-DEF), SEQ ID NO: 14 (CfEcR-EF), SEQ ID NO: 15(CfEcR-DE), SEQ ID NO: 16 (DmEcR-CDEF), SEQ ID NO: 17 (DmEcR-1/2CDEF),SEQ ID NO: 18 (DmEcR-DEF), SEQ ID NO: 19 (DmEcR-EF), and SEQ ID NO: 20(DmEcR-DE).

In a preferred embodiment, the isolated truncated RXR polypeptide isencoded by a polynucleotide comprising a polynucleotide sequenceselected from the group consisting of SEQ ID NO: 21 (MmRXR-CDEF), SEQ IDNO: 22 (MmRXR-DEF), SEQ ID NO: 23 (MmRXR-EF), SEQ ID NO: 24(MmRXR-truncatedEF), SEQ ID NO: 25 (MmRXR-E), SEQ ID NO: 26(HsRXR-CDEF), SEQ ID NO: 27 (HsRXR-DEF), SEQ ID NO: 28 (HsRXR-EF), SEQID NO: 29 (HsRXR-truncatedEF) and SEQ ID NO: 30 (HsRXR-E). In anotherpreferred embodiment, the isolated truncated RXR polypeptide comprisesan amino acid sequence selected from the group consisting of SEQ ID NO:31 (MmRXR-CDEF), SEQ ID NO: 32 (MmRXR-DEF), SEQ ID NO: 33 (MmRXR-EF),SEQ ID NO: 34 (MmRXR-truncatedEF), SEQ ID NO: 35 (MmRXR-E), SEQ ID NO:36 (HsRXR-CDEF), SEQ ID NO: 37 (HsRXR-DEF), SEQ ID NO: 38 (HsRXR-EF),SEQ ID NO: 39 (HsRXR-truncatedEF), and SEQ ID NO: 40 (HsRXR-E).

The present invention relates to an isolated EcR or RXR polypeptidecomprising a truncation mutation that reduces ligand binding activity orligand sensitivity of the EcR or RXR polypeptide, wherein thepolypeptide is encoded by a polynucleotide comprising a polynucleotidesequence selected from the group consisting of SEQ ID NO: 1(CfEcR-CDEF), SEQ ID NO: 2 (CfEcR-1/2CDEF), SEQ ID NO: 3 (CfEcR-DEF),SEQ ID NO: 4 (CfEcR-EF), SEQ ID NO: 5 (CfEcR-DE), SEQ ID NO: 6(DmEcR-CDEF), SEQ ID NO: 7 (DmEcR-1/2CDEF), SEQ ID NO: 8 (DmEcR-DEF),SEQ ID NO: 9 (DmEcR-EF), SEQ ID NO: 10 (DmEcR-DE), SEQ ID NO: 21(MmRXR-CDEF), SEQ ID NO: 22 (MmRXR-DEF), SEQ ID NO: 23 (MmRXR-EF), SEQID NO: 24 (MmRXR-truncatedEF), SEQ ID NO: 25 (MmRXR-E), SEQ ID NO: 26(HsRXR-CDEF), SEQ ID NO: 27 (HsRXR-DEF), SEQ ID NO: 28 (HsRXR-EF), SEQID NO: 29 (HsRXR-truncatedEF), and SEQ ID NO: 30 (HsRXR-E).

Thus, the present invention relates to an isolated truncated EcR or RXRpolypeptide comprising a truncation mutation that reduces ligand bindingactivity or ligand sensitivity of the EcR or RXR polypeptide, whereinthe polypeptide comprises an amino acid sequence selected from the groupconsisting of SEQ II) NO: 11 (CfEcR-CDEF), SEQ ID NO: 12(CfEcR-1/2CDEF), SEQ ID NO: 13 (CfEcR-DEF), SEQ ID NO: 14 (CfEcR-EF),SEQ ID NO: 15 (CfEcR-DE), SEQ ID NO: 16 (DmEcR-CDEF), SEQ ID NO: 17(DmEcR-1/2CDEF), SEQ ID NO: 18 (DmEcR-DEF), SEQ ID NO: 19 (DmEcR-EF),SEQ ID NO: 20 (DmEcR-DE), SEQ ID NO: 31 (MmRXR-CDEF), SEQ ID NO: 32(MmRXR-DEF), SEQ ID NO: 33 (MmRXR-EF), SEQ ID NO: 34(MmRXR-truncatedEF), SEQ ID NO: 35 (MmRXR-E), SEQ ID NO: 36(HsRXR-CDEF), SEQ ID NO: 37 (HsRXR-DEF), SEQ ID NO: 38 (HsRXR-EF), SEQID NO: 39 (HsRXR-tmncatedEF), and SEQ ID NO: 40 (HsRXR-E).

In a specific embodiment, the present invention relates to an isolatedEcR or RXR polypeptide comprising a truncation mutation that reducessteroid binding activity or steroid sensitivity of the EcR or RXRpolypeptide. In a preferred embodiment, the present invention relates toan isolated EcR polypeptide comprising a truncation mutation thatreduces steroid binding activity or steroid sensitivity of the EcRpolypeptide, wherein the EcR polypeptide is encoded by a polynucleotidecomprising a nucleic acid sequence of SEQ ID NO: 3 (CfEcR-DEF), SEQ IDNO: 4 (CfEcR-EF), SEQ ID NO: 8 (DmEcR-DEF), or SEQ ID NO: 9 (DmEcR-EF).Accordingly, the present invention also relates to an isolated truncatedEcR or RXR polypeptide comprising a truncation mutation that reducessteroid binding activity or steroid sensitivity of the EcR or RXRpolypeptide. In a preferred embodiment, the present invention relates toan isolated EcR polypeptide comprising a truncation mutation thatreduces steroid binding activity or steroid sensitivity of the EcRpolypeptide, wherein the EcR polypeptide comprises an amino acidsequence of SEQ ID NO: 13 (CfEcR-DEF), SEQ ID NO: 14 (CfEcR-EF), SEQ IDNO: 18 (DmEcR-DEF), or SEQ ID NO: 19 (DmEcR-EF).

In another specific embodiment, the present invention relates to anisolated EcR or RXR polypeptide comprising a truncation mutation thatreduces non-steroid binding activity or non-steroid sensitivity of theEcR or RXR polypeptide. In a preferred embodiment, the present inventionrelates to an isolated EcR polypeptide comprising a truncation mutationthat reduces non-steroid binding activity or non-steroid sensitivity ofthe EcR polypeptide, wherein the EcR polypeptide is encoded by apolynucleotide comprising a nucleic acid sequence of SEQ ID NO: 4(CfEcR-EF) or SEQ ID NO: 9 (DmEcR-EF). Accordingly, the presentinvention also relates to an isolated truncated EcR or RXR polypeptidecomprising a truncation mutation that reduces non-steroid bindingactivity or steroid sensitivity of the EcR or RXR polypeptide. In apreferred embodiment, the present invention relates to an isolated EcRpolypeptide comprising a truncation mutation that reduces non-steroidbinding activity or non-steroid sensitivity of the EcR polypeptide,wherein the EcR polypeptide comprises an amino acid sequence of SEQ IDNO: 14 (CfEcR-EF) or SEQ ID NO: 19 (DmEcR-EF).

In particular, the present invention relates to an isolated EcR or RXRpolypeptide comprising a truncation mutation that enhances ligandbinding activity or ligand sensitivity of the EcR or RXR polypeptide,wherein the polypeptide is encoded by a polynucleotide comprising apolynucleotide sequence selected from the group consisting of SEQ ID NO:1 (CfEcR-CDEF), SEQ ID NO: 2 (CfEcR-1/2CDEF), SEQ ID NO: 3 (CfEcR-DEF),SEQ ID NO: 4 (CfEcR-EF), SEQ ID NO: 5 (CfEcR-DE), SEQ ID NO: 6(DmEcR-CDEF), SEQ ID NO: 7 (DmEcR-1/2CDEF), SEQ ID NO: 8 (DmEcR-DEF),SEQ ID NO: 9 (DmEcR-EF), SEQ ID NO: 10 (DmEcR-DE), SEQ ID NO: 21(MmRXR-CDEF), SEQ ID NO: 22 (MmRXR-DEF), SEQ ID NO: 23 (MmRXR-EF), SEQID NO: 24 (MmRXR-truncatedEF), SEQ ID NO: 25 (MmRXR-E), SEQ ID NO: 26(HsRXR-CDEF), SEQ ID NO: 27 (HsRXR-DEF), SEQ ID NO: 28 (HsRXR-EF), SEQID NO: 29 (HsRXR-truncated EF), and SEQ ID NO: 30 (HsRXR-E).

The present invention relates to an isolated EcR or RXR polypeptidecomprising a truncation mutation that enhances ligand binding activityor ligand sensitivity of the EcR or RXR polypeptide, wherein thepolypeptide comprises an amino acid sequence selected from the groupconsisting of SEQ ID NO: 11 (CfEcR-CDEF), SEQ ID NO: 12 (CfEcR-1/2CDEF),SEQ ID NO: 13 (CfEcR-DEF), SEQ ID NO: 14 (CfEcR-EF), SEQ ID NO: 15(CfEcR-DE), SEQ ID NO: 16 (DmEcR-CDEF), SEQ ID NO: 17 (DmEcR-1/2CDEF),SEQ ID NO: 18 (DmEcR-DEF), SEQ ID NO: 19 (DmEcR-EF), SEQ ID NO: 20(DmEcR-DE), SEQ ID NO: 31 (MmRXR-CDEF), SEQ ID NO: 32 (MmRXR-DEF), SEQID NO: 33 (MmRXR-EF), SEQ ID NO: 34 (MmRXR-truncatedEF), SEQ ID NO: 35(MmRXR-E), SEQ ID NO: 36 (HsRXR-CDEF), SEQ ID NO: 37 (HsRXR-DEF), SEQ IDNO: 39 (HsRXR-EF), SEQ ID NO: 39 (HsRXR-truncatedEF), and SEQ ID NO: 40(HsRXR-E).

The present invention relates to an isolated EcR or RXR polypeptidecomprising a truncation mutation that enhances ligand binding activityor ligand sensitivity of the EcR or RXR polypeptide. In a specificembodiment, the present invention relates to an isolated EcR or RXRpolypeptide comprising a truncation mutation that enhances steroidbinding activity or steroid sensitivity of the EcR or RXR polypeptide.Accordingly, the present invention also relates to an isolated EcR orRXR polypeptide comprising a truncation mutation that enhances steroidbinding activity or steroid sensitivity of the EcR or RXR polypeptide.

In another specific embodiment, the present invention relates to anisolated EcR or RXR polypeptide comprising a truncation mutation thatenhances non-steroid binding activity or non-steroid sensitivity of theEcR or RXR polypeptide. In a preferred embodiment, the present inventionrelates to an isolated EcR polypeptide comprising a truncation mutationthat enhances non-steroid binding activity or non-steroid sensitivity ofthe EcR polypeptide, wherein the EcR polypeptide is encoded by apolynucleotide comprising a nucleic acid sequence of SEQ ID NO: 3(CfEcR-DEF) or SEQ ID NO: 8 (DmEcR-DEF). Accordingly, the presentinvention also relates to an isolated EcR or RXR polypeptide comprisinga truncation mutation that enhances non-steroid binding activity orsteroid sensitivity of the EcR or RXR polypeptide. In a preferredembodiment, the present invention relates to an isolated EcR polypeptidecomprising a truncation mutation that enhances non-steroid bindingactivity or non-steroid sensitivity of the EcR polypeptide, wherein theEcR polynucleotide comprises an amino acid sequence of SEQ ID NO: 13(CfEcR-DEF) or SEQ ID NO: 18 (DmEcR-DEF).

The present invention also relates to an isolated retinoid X receptorpolypeptide comprising a truncation mutation that increases ligandsensitivity of a heterodimer comprising the mutated retinoid X receptorpolypeptide and a dimerization partner. Preferably, the isolatedretinoid X receptor polypeptide comprising a truncation mutation thatincreases ligand sensitivity of a heterodimer is encoded by apolynucleotide comprising a nucleic acid sequence selected from thegroup consisting of SEQ ID NO: 23 (MmRXR-EF), SEQ ID NO: 24(MmRXR-truncatedEF), SEQ ID NO: 28 (HsRXR-EF), or SEQ ID NO: 29(HsRXR-truncatedEF). More preferably, the isolated polynucleotideencoding a retinoid X receptor polypeptide comprising a truncationmutation that increases ligand sensitivity of a heterodimer comprises anamino acid sequence selected from the group consisting of SEQ ID NO: 33(MmRXR-EF), SEQ ID NO: 34 (MmRXR-truncatedEF), SEQ ID NO: 38 (HsRXR-EF),or SEQ ID NO: 39 (HsRXR-truncatedEF).

In a specific embodiment, the dimerization partner is an ecdysonereceptor polypeptide. Preferably, the dimerization partner is atruncated EcR polypeptide. More preferably, the dimerization partner isan EcR polypeptide in which domains A/B/C have been deleted. Even morepreferably, the dimerization partner is an EcR polypeptide comprising anamino acid sequence of SEQ ID NO: 13 (CfEcR-DEF) or SEQ ID NO: 18(DmEcR-DEF).

Method of Modulating Gene Expression of the Invention

Applicants' invention also relates to methods of modulating geneexpression in a host cell using a gene expression modulation systemaccording to the invention. Specifically, Applicants' invention providesa method of modulating the expression of a gene in a host cellcomprising the steps of: a) introducing into the host cell a geneexpression modulation system according to the invention; and b)introducing into the host cell a ligand that independently combines withthe ligand binding domains of the first polypeptide and the secondpolypeptide of the gene expression modulation system; wherein the geneto be expressed is a component of a gene expression cassette comprising:i) a response element comprising a domain to which the DNA bindingdomain of the first polypeptide binds; ii) a promoter that is activatedby the transactivation domain of the second polypeptide; and a genewhose expression is to be modulated, whereby a complex is formedcomprising the ligand, the first polypeptide of the gene expressionmodulation system and the second polypeptide of the gene expressionmodulation system, and whereby the complex modulates expression of thegene in the host cell.

Genes of interest for expression in a host cell using Applicants'methods may be endogenous genes or heterologous genes. Nucleic acid oramino acid sequence information for a desired gene or protein can belocated in one of many public access databases, for example, GENBANK,EMBL, Swiss-Prot, and PIR, or in many biology related journalpublications. Thus, those skilled in the art have access to nucleic acidsequence information for virtually all known genes. Such information canthen be used to construct the desired constructs for the insertion ofthe gene of interest within the gene expression cassettes used inApplicants' methods described herein.

Examples of genes of interest for expression in a host cell usingApplicants' methods include, but are not limited to: antigens producedin plants as vaccines, enzymes like alpha-amylase, phytase, glucans, andxylanse, genes for resistance against insects, nematodes, fungi,bacteria, viruses, and abiotic stresses, nutraceuticals,pharmaceuticals, vitamins, genes for modifying amino acid content,herbicide resistance, cold, drought, and heat tolerance, industrialproducts, oils, protein, carbohydrates, antioxidants, male sterileplants, flowers, fuels, other output traits, genes encodingtherapeutically desirable polypeptides or products, such as genes thatcan provide, modulate, alleviate, correct and/or restore polypeptidesimportant in treating a condition, a disease, a disorder, a dysfunction,a genetic defect, and the like.

Acceptable ligands are any that modulate expression of the gene whenbinding of the DNA binding domain of the two hybrid system to theresponse element in the presence of the ligand results in activation orsuppression of expression of the genes. Preferred ligands includeponasterone, muristerone A, N,N′-diacylhydrazines such as thosedisclosed in U.S. Pat. Nos. 6,013,836; 5,117,057; 5,530,028; and5,378,726; dibenzoylalkyl cyanohydrazines such as those disclosed inEuropean Application No. 461,809; N-alkyl-N,N′-diacylhydrazines such asthose disclosed in U.S. Pat. No. 5,225,443;N-acyl-N-alkylcarbonylhydrazines such as those disclosed in EuropeanApplication No. 234,994; N-aroyl-N-alkyl-N′-aroylhydrazines such asthose described in U.S. Pat. No. 4,985,461; each of which isincorporated herein by reference and other similar materials including3,5-di-tert-butyl-4-hydroxy-N-isobutyl-benzamide, 8-O-acetylharpagide,and the like.

Preferably, the ligand for use in Applicants' method of modulatingexpression of gene is a compound of the formula:

wherein:

-   -   E is a (C₄-C₆)alkyl containing a tertiary carbon or a        cyano(C₃-C₅)alkyl containing a tertiary carbon;    -   R¹ is H, Me, Et, i-Pr, F, formyl, CF₃, CHF₂, CHCl₂, CH₂F, CH₂Cl,        CH₂OH, CH₂OMe, CH₂CN, CN,C≡CII,1-propynyl, 2-propynyl, vinyl,        OH, OMe, OEt, cyclopropyl, CF₂CF₃, CH═CHCN, allyl, azido, SCN,        or SCHF₂;    -   R² is H, Me, Et, n-Pr, i-Pr, formyl, CF₃, CHF₂, CHCl₂, CH₂F,        CH₂Cl, CH₂OH, CH₂OMe, CH₂CN, CN,C≡CII,1-propynyl, 2-propynyl,        vinyl, Ac, F, Cl, OH, OMe, OEt, O-n-Pr, OAc, NMe2, NEt₂, SMe,        SEt, SOCF₃, OCF₂CF₂H, COEt, cyclopropyl, CF₂CF₃, CH═CHCN, allyl,        azido, OCF₃, OCHF₂, O-i-Pr, SCN, SCHF₂, SOMe, NH—CN, or joined        with R³ and the phenyl carbons to which R² and R³ are attached        to form an ethylenedioxy, a dihydrofuryl ring with the oxygen        adjacent to a phenyl carbon, or a dihydropyryl ring with the        oxygen adjacent to a phenyl carbon;    -   R³ is H, Et, or joined with R² and the phenyl carbons to which        R² and R³ are attached to form an ethylenedioxy, a dihydrofuryl        ring with the oxygen adjacent to a phenyl carbon, or a        dihydropyryl ring with the oxygen adjacent to a phenyl carbon;    -   R⁴, R⁵, and R⁶ are independently H, Me, Et, F, Cl, Br, formyl,        CF₅, CHF₂, CH₂F, CH2Cl, CH₂OH, CN,C≡CII,1-propynyl, 2-propynyl,        vinyl, OMe, OEt, SMe, or SEt.

Applicants' invention provides for modulation of gene expression inprokaryotic and eukaryotic host cells. Thus, the present invention alsorelates to a method for modulating gene expression in a host cellselected from the group consisting of a bacterial cell, a fungal cell, ayeast cell, a plant cell, an animal cell, and a mammalian cell.Preferably, the host cell is a yeast cell, a plant cell, a murine cell,or a human cell.

Expression in transgenic host cells may be useful for the expression ofvarious polypeptides of interest including but not limited totherapeutic polypeptides, pathway intermediates; for the modulation ofpathways already existing in the host for the synthesis of new productsheretofore not possible using the host; cell based assays; and the like.Additionally the gene products may be useful for conferring highergrowth yields of the host or for enabling alternative growth mode to beutilized.

Host Cells and Non-Human Organisms of the Invention

As described above, the gene expression modulation system of the presentinvention may be used to modulate gene expression in a host cell.Expression in transgenic host cells may be useful for the expression ofvarious genes of interest. Thus, Applicants' invention also provides anisolated host cell comprising a gene expression system according to theinvention. The present invention also provides an isolated host cellcomprising a gene expression cassette according to the invention.Applicants' invention also provides an isolated host cell comprising apolynucleotide or polypeptide according to the invention. The isolatedhost cell may be either a prokaryotic or a eukaryotic host cell.

Preferably, the host cell is selected from the group consisting of abacterial cell, a fungal cell, a yeast cell, a plant cell, an animalcell, and a mammalian cell. Examples of preferred host cells include,but are not limited to, fungal or yeast species such as Aspergillus,Trichoderma, Saccharomyces, Pichia, Candida, Hansenula, or bacterialspecies such as those in the genera Synechocystis, Synechococcus,Salmonella, Bacillus, Acinetobacter, Rhodococcus, Streptomyces,Escherichia, Pseudomonas, Methylomonas, Methylobacter, Alcaligenes,Synechocystis, Anabaena, Thiobacillus, Methanobacterium and Klebsiella,plant, animal, and mammalian host cells. More preferably, the host cellis a yeast cell, a plant cell, a murine cell, or a human cell.

In a specific embodiment, the host cell is a yeast cell selected fromthe group consisting of a Saccharomyces, a Pichia, and a Candida hostcell.

In another specific embodiment, the host cell is a plant cell selectedfrom the group consisting of an apple, Arabidopsis, bajra, banana,barley, bean, beet, blackgram, chickpea, chili, cucumber, eggplant,favabean, maize, melon, millet, mungbean, oat, okra, Panicum, papaya,peanut, pea, pepper, pigeonpea, pineapple, Phaseolus, potato, pumpkin,rice, sorghum, soybean, squash, sugarcane, sugarbeet sunflower, sweetpotato, tea, tomato, tobacco, watermelon, and wheat host cell.

In another specific embodiment, the host cell is a murine cell.

In another specific embodiment, the host cell is a human cell.

Host cell transformation is well known in the art and may be achieved bya variety of methods including but not limited to electroporation, viralinfection, plasmid/vector transfection, non-viral vector mediatedtransfection, Agrobacterium-mediated transformation, particlebombardment, and the like. Expression of desired gene products involvesculturing the transformed host cells under suitable conditions andinducing expression of the transformed gene. Culture conditions and geneexpression protocols in prokaryotic and eukaryotic cells are well knownin the art (see General Methods section of Examples). Cells may beharvested and the gene products isolated according to protocols specificfor the gene product.

In addition, a host cell may be chosen which modulates the expression ofthe inserted polynucleotide, or modifies and processes the polypeptideproduct in the specific fashion desired. Different host cells havecharacteristic and specific mechanisms for the translational andpost-translational processing and modification (e.g., glycosylation,cleavage [e.g., of signal sequence]) of proteins. Appropriate cell linesor host systems can be chosen to ensure the desired modification andprocessing of the foreign protein expressed. For example, expression ina bacterial system can be used to produce a non-glycosylated coreprotein product. However, a polypeptide expressed in bacteria may not beproperly folded. Expression in yeast can produce a glycosylated product.Expression in eukaryotic cells can increase the likelihood of “native”glycosylation and folding of a heterologous protein. Moreover,expression in mammalian cells can provide a tool for reconstituting, orconstituting, the polypeptide's activity. Furthermore, differentvector/host expression systems may affect processing reactions, such asproteolytic cleavages, to a different extent.

Applicants' invention also relates to a non-human organism comprising anisolated host cell according to the invention. Preferably, the non-humanorganism is selected from the group consisting of a bacterium, a fungus,a yeast, a plant, an animal, and a mammal. More preferably, thenon-human organism is a yeast, a plant, a mouse, a rat, a rabbit, a cat,a dog, a bovine, a goat, a pig, a horse, a sheep, a monkey, or achimpanzee.

In a specific embodiment, the non-human organism is a yeast selectedfrom the group consisting of Saccharomyces, Pichia, and Candida.

In another specific embodiment, the non-human organism is a plantselected from the group consisting of an apple, Arabidopsis, bajra,banana, barley, beans, beet, blackgram, chickpea, chili, cucumber,eggplant, favabean, maize, melon, millet, mungbean, oat, okra, Panicum,papaya, peanut, pea, pepper, pigeonpea, pineapple, Phaseolus, potato,pumpkin, rice, sorghum, soybean, squash, sugarcane, sugarbeet,sunflower, sweet potato, tea, tomato, tobacco, watermelon, and wheat.

In another specific embodiment, the non-human organism is a Mus musculusmouse.

Measuring Gene Expression/Transcription

One useful measurement of Applicants' methods of the invention is thatof the transcriptional state of the cell including the identities andabundances of RNA, preferably mRNA species. Such measurements areconveniently conducted by measuring cDNA abundances by any of severalexisting gene expression technologies.

Nucleic acid array technology is a useful technique for determiningdifferential mRNA expression. Such technology includes, for example,oligonucleotide chips and DNA microarrays. These techniques rely on DNAfragments or oligonucleotides which correspond to different genes orcDNAs which are immobilized on a solid support and hybridized to probesprepared from total mRNA pools extracted from cells, tissues, or wholeorganisms and converted to cDNA. Oligonucleotide chips are arrays ofoligonucleotides synthesized on a substrate using photolithographictechniques. Chips have been produced which can analyze for up to 1700genes. DNA microarrays are arrays of DNA samples, typically PCRproducts, that are robotically printed onto a microscope slide. Eachgene is analyzed by a full or partial length target DNA sequence. Microarrays with up to 10,000 genes are now routinely prepared commercially.The primary difference between these two techniques is thatoligonucleotide chips typically utilize 25-mer oligonucleotides whichallow fractionation of short DNA molecules whereas the larger DNAtargets of microarrays, approximately 1000 base pairs, may provide moresensitivity in fractionating complex DNA mixtures.

Another useful measurement of Applicants' methods of the invention isthat of determining the translation state of the cell by measuring theabundances of the constituent protein species present in the cell usingprocesses well known in the art.

Where identification of genes associated with various physiologicalfunctions is desired, an assay may be employed in which changes in suchfunctions as cell growth, apoptosis, senescence, differentiation,adhesion, binding to a specific molecules, binding to another cell,cellular organization, organogenesis, intracellular transport, transportfacilitation, energy conversion, metabolism, myogenesis, neurogenesis,and/or hematopoiesis is measured.

In addition, selectable marker or reporter gene expression may be usedto measure gene expression modulation using Applicants' invention.

Other methods to detect the products of gene expression are well knownin the art and include Southern blots (DNA detection), dot or slot blots(DNA, RNA), Northern blots (RNA), and RT-PCR (RNA) analyses. Althoughless preferred, labeled proteins can be used to detect a particularnucleic acid sequence to which it hybridizes.

In some cases it is necessary to amplify the amount of a nucleic acidsequence. This may be carried out using one or more of a number ofsuitable methods including, for example, polymerase chain reaction(“PCR”), ligase chain reaction (“LCR”), strand displacementamplification (“SDA”), transcription-based amplification, and the like.PCR is carried out in accordance with known techniques in which, forexample, a nucleic acid sample is treated in the presence of a heatstable DNA polymerase, under hybridizing conditions, with oneoligonucleotide primer for each strand of the specific sequence to bedetected. An extension product of each primer that is synthesized iscomplementary to each of the two nucleic acid strands, with the primerssufficiently complementary to each strand of the specific sequence tohybridize therewith. The extension product synthesized from each primercan also serve as a template for further synthesis of extension productsusing the same primers. Following a sufficient number of rounds ofsynthesis of extension products, the sample may be analyzed as describedabove to assess whether the sequence or sequences to be detected arepresent.

The present invention may be better understood by reference to thefollowing non-limiting Examples, which are provided as exemplary of theinvention.

EXAMPLES General Methods

Standard recombinant DNA and molecular cloning techniques used hereinare well known in the art and are described by Sambrook, J., Fritsch, E.F. and Maniatis, T. Molecular Cloning: A Laboratory Manual; Cold SpringHarbor Laboratory Press: Cold Spring Harbor, (1989) (Maniatis) and by T.J. Silhavy, M. L. Bennan, and L. W. Enquist, Experiments with GeneFusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1984)and by Ausubel, F. M. et al., Current Protocols in Molecular Biology,Greene Publishing Assoc. and Wiley-Interscience (1987).

Methods for plant tissue culture, transformation, plant molecularbiology, and plant, general molecular biology may be found in PlantTissue Culture Concepts and Laboratory Exercises edited by R N Trigianoand D J Gray, 2^(nd) edition, 2000, CRC press, New York; AgrobacteriumProtocols edited by K M A Gartland and M R Davey, 1995, Humana Press,Totowa, N.J.; Methods in Plant Molecular Biology, P. Maliga et al.,1995, Cold Spring Harbor Lab Press, New York; and Molecular Cloning, J.Sambrook et al., 1989, Cold Spring Harbor Lab Press, New York.

Materials and methods suitable for the maintenance and growth ofbacterial cultures are well known in the art. Techniques suitable foruse in the following examples may be found as set out in Manual ofMethods for General Bacteriology (Phillipp Gerhardt, R. G. E. Murray,Ralph N. Costilow, Eugene W. Nester, Willis A. Wood, Noel R. Krieg andG. Briggs Phillips, eds), American Society for Microbiology, Washington,D.C. (1994)) or by Thomas D. Brock in Biotechnology: A Textbook ofIndustrial Microbiology, Second Edition, Sinauer Associates, Inc.,Sunderland, Mass. (1989). All reagents, restriction enzymes andmaterials used for the growth and maintenance of host cells wereobtained from Aldrich Chemicals (Milwaukee, Wis.), DIFCO Laboratories(Detroit, Mich.), GIBCO/BRL (Gaithersburg, Md.), or Sigma ChemicalCompany (St. Louis, Mo.) unless otherwise specified.

Manipulations of genetic sequences may be accomplished using the suiteof programs available from the Genetics Computer Group Inc. (WisconsinPackage Version 9.0, Genetics Computer Group (GCG), Madison, Wis.).Where the GCG program “Pileup” is used the gap creation default value of12, and the gap extension default value of 4 may be used. Where the CGC“Gap” or “Bestfit” programs is used the default gap creation penalty of50 and the default gap extension penalty of 3 may be used. In any casewhere GCG program parameters are not prompted for, in these or any otherGCG program, default values may be used.

The meaning of abbreviations is as follows: “h” means hour(s), “min”means minute(s), “sec” means second(s), “d” means day(s), “μl” meansmicroliter(s), “ml” means milliliter(s), “L” means liter(s), “μM” meansmicromolar, “mM” means millimolar, “μg” means microgram(s), “mg” meansmilligram(s), “A” means adenine or adenosine, “T” means thymine orthymidine, “G” means guanine or guanosine, “C” means cytidine orcytosine, “x g” means times gravity, “nt” means nucleotide(s), “aa”means amino acid(s), “bp” means base pair(s), “kb” means kilobase(s),“k” means kilo, “μ” means micro, and “C” means degrees Celsius.

Example 1

Applicants' improved EcR-based inducible gene modulation system wasdeveloped for use in various applications including gene therapy,expression of proteins of interest in host cells, production oftransgenic organisms, and cell-based assays. This Example describes theconstruction and evaluation of several gene expression cassettes for usein the EcR-based inducible gene expression system of the invention.

In various cellular backgrounds, including mammalian cells, insectecdysone receptor (EcR) heterodimerizes with retinoid X receptor (RXR)and, upon binding of ligand, transactivates genes under the control ofecdysone response elements. Applicants constructed several EcR-basedgene expression cassettes based on the spruce budworm Choristoneurafumiferana EcR (“CfEcR”; full length polynucleotide and amino acidsequences are set forth in SEQ ID NO: 49 and SEQ ID NO: 50,respectively), C. fumiferana ultraspiracle (“CfUSP”; full lengthpolynucleotide and amino acid sequences are set forth in SEQ ID NO: 51and SEQ ID NO: 52, respectively), and mouse Mus musculus RXRα (MmRXRα;full length polynucleotide and amino acid sequences are set forth in SEQID NO: 53 and SEQ ID NO: 54, respectively). The prepared receptorconstructs comprise a ligand binding domain of EcR and of RXR or of USP;a DNA binding domain of GAL4 or of EcR; and an activation domain ofVP16. The reporter constructs include a reporter gene, luciferase orLacZ, operably linked to a synthetic promoter construct that compriseseither GAL4 or EcR/USP binding sites (response elements). Variouscombinations of these receptor and reporter constructs werecotransfected into CHO, NIH3T3, CV1 and 293 cells. Gene inductionpotential (magnitude of induction) and ligand specificity andsensitivity were examined using four different ligands: two steroidalligands (ponasterone A and muristerone A) and two non-steroidal ligands(N-(2-ethyl-3-methoxybenzoyl)-N′-(3,5-dimethylbenzoyl)-N′-tert-butylhydrazineandN-(3,4-(1,2-ethylenedioxy)-2-methylbenzoyl)-N′-(3,5-dimethylbenzoyl)-N′-tert-butylhydrazine)in a dose-dependent induction of reporter gene expression in thetransfected cells. Reporter gene expression activities were assayed at24 hr or 48 hr after ligand addition.

Gene Expression Cassettes: Ecdysone receptor-based, chemically induciblegene expression cassettes (switches) were constructed as followed, usingstandard cloning methods available in the art. The following is briefdescription of preparation and composition of each switch.

1.1—GAL4EcR/VP16RXR: The D, E, and F domains from spruce budwormChoristoneura fumiferana EcR (“CfEcRDEF”; SEQ ID NO: 3) were fused toGAL4 DNA binding domain (“DNABD”; SEQ ID NO: 41) and placed under thecontrol of an SV40e promoter (SEQ ID NO: 55). The DEF domains from mouse(Mus musculus) RXR (“MmRXRDEF”; SEQ ID NO: 22) were fused to theactivation domain from VP16 (“VP16AD”; SEQ ID NO: 45) and placed underthe control of an SV40e promoter (SEQ ID NO: 55). Five consensus GAL4binding sites (“5XGAL4RE”; comprising 5, GAL4RE comprising SEQ ID NO:47) were fused to a synthetic E1b minimal promoter (SEQ ID NO: 56) andplaced upstream of the luciferase gene (SEQ ID NO: 57).

1.2—GAL4EcR/VP16USP: This construct was prepared in the same way as inswitch 1.1 above except MmRXRDEF was replaced with the D, E and Fdomains from spruce budworm USP (“CfUSPDEF”; SEQ ID NO: 58). Theconstructs used in this example are similar to those disclosed in U.S.Pat. No. 5,880,333 except that Choristoneura fumiferana USP rather thanDrosophila melanogaster USP was utilized.

1.3—GAL4RXR/VP16CfEcR: MmRXRDEF (SEQ ID NO: 22) was fused to a GAL4DNABD(SEQ ID NO: 41) and CfEcRCDEF (SEQ ID NO: 1) was fused to a VP16AD (SEQED NO: 45).

1.4—GAL4RXR/VP16DmEcR: This construct was prepared in the same way asswitch 1.3 except CfEcRCDEF was replaced with DmEcRCDEF (SEQ ID NO: 6).

1.5—AL4USP/VP16CfEcR: This construct was prepared in the same way asswitch 1.3 except MmRXRDEF was replaced with CfUSPDEF (SEQ ID NO: 58).

1.6—GAL4RXRCfEcRVP16: This construct was prepared so that both the GAL4DNABD and the VP16AD were placed on the same molecule. GAL4DNABD (SEQ IDNO: 41) and VP16AD (SEQ ID NO: 45) were fused to CfEcRDEF (SEQ ID NO: 3)at N- and C-termini respectively. The fusion was placed under thecontrol of an SV40e promoter (SEQ ID NO: 55).

1.7—VP16CfEcR: This construct was prepared such that CfEcRCDEF (SEQ IDNO: 1) was fused to VP16AD (SEQ ID NO: 45) and placed under the controlof an SV40e promoter (SEQ ID NO: 55). Six ecdysone response elements(“EcRE”; SEQ ID NO: 59) from the hsp27 gene were placed upstream of thepromoter and a luciferase gene (SEQ ID NO: 57). This switch mostprobably uses endogenous RXR.

1.8—DmVgRXR: This system was purchased from Invitrogen Corp., Carlsbad,Calif. It comprises a Drosophila melanogaster EcR (“DmEcR”) with amodified DNABD fused to VP16AD and placed under the control of a CMVpromoter (SEQ ID NO: 60). Full length MmRXR (SEQ ID NO: 53) was placedunder the control of the RSV promoter (SEQ ID NO: 61). The reporter,pIND(SP1)LacZ, contains five copies of a modified ecdysone responseelement (“EcRE”, E/GRE), three copies of an SP1 enhancer, and a minimalheat shock promoter, all of which were placed upstream to the LacZreporter gene.

1.9—CfVgRXR: This example was prepared in the same way as switch 1.8except DinEcR was replaced with a truncated CfEcR comprising a partialA/B domain and the complete CDEF domains [SEQ ID NO: 62 (polynucleotide)and SEQ ID NO: 63 (polypeptide)].

1.10—CfVgRXRdel: This example was prepared in the same way as switch 1.9except MmRXR (SEQ ID NO: 53) was deleted.

Cell lines: Four cell lines: CHO, Chinese hamster Cricetulus griseusovarian cell line; NIH3T3 (3T3) mouse Mus musculus cell line; 293 humanHomo sapiens kidney cell line, and CV1 African green monkey kidney cellline were used in these experiments. Cells were maintained in theirrespective media and were subcultured when they reached 60% confluency.Standard methods for culture and maintenance of the cells were followed.

Transfections: Several commercially available lipofactors as well aselectroporation methods were evaluated and the best conditions fortransfection of each cell line were developed. CHO, NIH3T3, 293 and CV1cells were grown to 60% confluency. DNAs corresponding, to the variousswitch constructs outlined in Examples 1.1 through 1.10 were transfectedinto CHO cells, NIH3T3 cells, 293 cells, or CV1 cells as follows.

CHO cells: Cells were harvested when they reach 60-80% confluency andplated in 6- or 12- or 24- well plates at 250,000, 100,000, or 50,000cells in 2.5, 1.0, or 0.5 ml of growth medium containing 10% Fetalbovine serum respectively. The next day, the cells were rinsed withgrowth medium and transfected for four hours. LipofectAMINE™ 2000 (LifeTechnologies Inc,) was found to be the best transfection reagent forthese cells. For 12- well plates, 4 μl of LipofectAMINE™ 2000 was mixedwith 100 μl of growth medium. 1.0 μg of reporter construct and 0.25 μgof receptor construct(s) were added to the transfection mix. A secondreporter construct was added [pTKRL (Promega), 0.1 μg/transfection mix]and comprised a Renilla luciferase gene (SEQ ID NO: 64) operably linkedand placed under the control of a thymidine kinase (TK) constitutivepromoter and was used for normalization. The contents of thetransfection mix were mixed in a vortex mixer and let stand at roomtemperature for 30 min. At the end of incubation, the transfection mixwas added to the cells maintained in 400 μl growth medium. The cellswere maintained at 37° C. and 5% CO₂ for four hours. At the end ofincubation, 500 μl of growth medium containing 20% FBS and either DMSO(control) or a DMSO solution of appropriate ligands were added and thecells were maintained at 37° C. and 5% CO₂ for 24-48 hr. The cells wereharvested and reporter activity was assayed. The same procedure wasfollowed for 6 and 24 well plates as well except all the reagents weredoubled for 6 well plates and reduced to half for 24-well plates.

NIH3T3 Cells: Superfect™ (Qiagen Inc.) was found to be the besttransfection reagent for 3T3 cells. The same procedures described forCHO cells were followed for 3T3 cells as well with two modifications.The cells were plated when they reached 50% confluency. 125,000 or50,000 or 25,000 cells were plated per well of 6- or 12- or 24-wellplates respectively. The GAl4EcR/VP16RXR and reporter vector DNAs weretransfected into NIH3T3 cells, the transfected cells were grown inmedium containing PonA, MurA,N-(2-ethyl-3-methoxybenzoyl)-N′-(3,5-dimethylbenzoyl)-N′-t-butylhydrazine,orN-(3,4-(1,2-ethylenedioxy)-2-methylbenzoyl)-N′-(3,5-dimethylbenzoyl)-N′-tert-butylhydrazinefor 48 hr. The ligand treatments were performed as described in the CHOcell section above.

293 Cells: LipofectAMINE™ 2000 (Life Technologies) was found to be thebest lipofactor for 293 cells. The same procedures described for CHOwere followed for 293 cells except that the cells were plated inbiocoated plates to avoid clumping. The ligand treatments were performedas described in the CHO cell section above.

CV1 Cells: LipofectAMINE™ plus (Life Technologies) was found to be thebest lipofactor for CV1 cells. The same procedures described for NIH3T3cells were followed for CV1 cells

Ligands: Ponasterone A and Muristerone A were purchased from SigmaChemical Company. The two non-steroidsN-(2-ethyl-3-methoxybenzoyl)-N′-(3,5-dimethylbenzoyl)-N′-t-butylhydrazine,orN-(3,4-(1,2-ethylenedioxy)-2-methylbenzoyl)-N′-(3,5-dimethylbenzoyl)-N′-tert-butylhydrazineare synthetic stable ecdysteroids synthesized at Rohm and Haas Company.All ligands were dissolved in DMSO and the final concentration of DMSOwas maintained at 0.1% in both controls and treatments.

Reporter Assays: Cells were harvested 24-48 hr after adding ligands.125, 250, or 500 μl of passive lysis buffer (part of Dual-luciferase™reporter assay system from Promega Corporation) were added to each wellof 24- or 12- or 24-well plates respectively. The plates were placed ona rotary shaker for 15 min. Twenty μl of lysate was assayed. Luciferaseactivity was measured using Dual-luciferase™ reporter assay system fromPromega Corporation following the manufacturer's instructions.β-Galactosidase was measured using Galacto-Star™ assay kit from TROPIXfollowing the manufacturer's instructions. All luciferase andβ-galactosidase activities were normalized using Renilla luciferase as astandard. Fold activities were calculated by dividing normalizedrelative light units (“RLU”) in ligand treated cells with normalized RLUin DMSO treated cells (untreated control).

The results of these experiments are provided in the following tables.

TABLE 1 Transactivation of reporter genes through various switches inCHO cells Mean Fold Activation with 50 μM N-(2-ethyl-3-methoxybenzoyl)-N′-(3,5-dimethylbenzoyl)-N′-t- Composition of Switch butylhydrazine 1.1GAL4EcR + VP16RXR 267 pGAL4RELuc 1.2 GAL4EcR + VP16USP 2 pGAL4RELuc 1.3GAL4RXR + VP16CfEcR 85 pGAL4RELuc 1.4 GAL4RXR + VP16DmEcR 312 pGAL4RELuc1.5 GAL4USP + VP16CfEcR 2 pGAL4RELuc 1.6 GAL4CfEcRVP16 9 pGAL4RELuc 1.7VP16CfEcR 36 pEcRELuc 1.8 DmVgRXR + MmRXR 14 pIND(SP1)LacZ 1.9 CfVgRXR +MmRXR 27 pIND(SP1)LacZ 1.10 CfVgRXR 29 pIND(SP1)LacZ

TABLE 2 Transactivation of reporter genes through various switches in3T3 cells Mean Fold Activation Through N-(2-ethyl-3-methoxybenzoyl)-N′-(3,5- Composition of Switchdimethylbenzoyl)-N′-t-butylhydrazine 1.1 GAL4EcR + VP16RXR 1118pGAL4RELuc 1.2 GAL4EcR + VP16USP 2 pGAL4RELuc 1.3 GAL4RXR + VP16CfEcR 47pGAL4RELuc 1.4 GAL4RXR + VP16DmEcR 269 pGAL4RELuc 1.5 GAL4USP +VP16CfEcR 3 pGAL4RELuc 1.6 GAL4CfEcRVP16 7 pGAL4RELuc 1.7 VP16CfEcR 1pEcRELuc 1.8 DmVgRXR + MmRXR 21 pIND(SP1)LacZ 1.9 CfVgRXR + MmRXR 19pIND(SP1)LacZ 1.10 CfVgRXR 2 pIND(SP1)LacZ

TABLE 3 Transactivation of reporter genes through various switches in293 cells Mean Fold Activation Through N-(2-ethyl-3-methoxybenzoyl)-N′-(3,5- Composition of Switchdimethylbenzoyl)-N′-t-butylhydrazine 1.1 GAL4EcR + VP16RXR 125pGAL4RELuc 1.2 GAL4EcR + VP16USP 2 pGAL4RELuc 1.3 GAL4RXR + VP16CfEcR 17pGAL4RELuc 1.4 GAL4RXR + VP16DmEcR 3 pGAL4RELuc 1.5 GAL4USP + VP16CfEcR2 pGAL4RELuc 1.6 GAL4CfEcRVP16 3 pGAL4RELuc 1.7 VP16CfEcR 2 pEcRELuc 1.8DmVgRXR + MmRXR 21 pIND(SP1)LacZ 1.9 CfVgRXR + MmRXR 12 pIND(SP1)LacZ1.10 CfVgRXR 3 pIND(SP1)LacZ

TABLE 4 Transactivation of reporter genes through various switches inCV1 cells Mean Fold Activation Through N-(2-ethyl-3-methoxybenzoyl)-N′-(3,5- Composition of Switchdimethylbenzoyl)-N′-t-butylhydrazine 1.1 GAL4EcR + VP16RXR 279pGAL4RELuc 1.2 GAL4EcR + VP16USP 2 pGAL4RELuc 1.3 GAL4RXR + VP16CfEcR 25pGAL4RELuc 1.4 GAL4RXR + VP16DmEcR 80 pGAL4RELuc 1.5 GAL4USP + VP16CfEcR3 pGAL4RELuc 1.6 GAL4CfEcRVP16 6 pGAL4RELuc 1.7 VP16CfEcR 1 pEcRELuc 1.8DmVgRXR + MmRXR 12 pIND(SP1)LacZ 1.9 CfVgRXR + MmRXR 7 pIND(SP1)LacZ1.10 CfVgRXR 1 pIND(SP1)LacZ

TABLE 5 Transactivation of reporter gene GAL4CfEcRDEF/VP16MmRXRDEF(switch 1.1) through steroids and non-steroids in 3T3 cells. Mean FoldInduction at 1.0 μM Ligand Concentration 1. Ponasterone A 1.0 2.Muristerone A 1.0 3. N-(2-ethyl-3-methoxybenzoyl)-N′-(3,5- 116dimethylbenzoyl)-N′-tert-butylhydrazine 4.N′-(3,4-(1,2-ethylenedioxy)-2-methylbenzoyl)-N′- 601(3,5-dimethylbenzoyl)-N′-tert-butylhydrazine

TABLE 6 Transactivation of reporter gene GAL4MmRXRDEF/VP16CfEcRCDEF(switch 1.3) through steroids and non-steroids in 3T3 cells. Mean FoldInduction at 1.0 μM Ligand Concentration 1. Ponasterone A 1.0 2.Muristerone A 1.0 3. N-(2-ethyl-3-methoxybenzoyl)-N′-(3,5- 71dimethylbenzoyl)-N′-tert-butylhydrazine 4.N′-(3,4-(1,2-ethylenedioxy)-2-methylbenzoyl)-N′- 54(3,5-dimethylbenzoyl)-N′-tert-butylhydrazine

Applicants' results demonstrate that the non-steroidal ecdysoneagonists,N-(2-ethyl-3-methoxybenzoyl)-N′-(3,5-dimethylbenzoyl)-N′-tert-butylhydrazineandN′-(3,4-(1,2-ethylenedioxy)-2-methylbenzoyl)-N′-(3,5-dimethylbenzoyl)-N′-tert-butylhydrazine,were more potent activators of CfEcR as compared to Drosophilamelanogaster EcR (DmEcR). (see Tables 1-4). Also, in the mammalian celllines tested, MmRXR performed better than CfUSP as a heterodimericpartner for CfEcR. (see Tables 1-4). Additionally, Applicants' induciblegene expression modulation system performed better when exogenous MmRXRwas used than when the system relied only on endogenous RXR levels (seeTables 1-4).

Applicants' results also show that in a CfEcR-based inducible geneexpression system, the non-steroidal ecdysone agonists induced reportergene expression at a lower concentration (i.e., increased ligandsensitivity) as compared to the steroid ligands, ponasterone A andmuristerone A (see Tables 5 and 6).

Out of 10 EcR based gene switches tested, the GAL4EcR/VP16RXR switch(Switch 1.1) performed better than any other switch in all four celllines examined and was more sensitive to non-steroids than steroids. Theresults also demonstrate that placing the activation domain (AD) and DNAbinding domain (DNABD) on each of the two partners reduced backgroundwhen compared to placing both AD and DNABD together on one of the twopartners. Therefore, a switch format where the AD and DNABD areseparated between two partners, works well for EcR-based gene switchapplications.

In addition, the MmRXR/EcR-based switches performed better thanCfUSP/EcR-based switches, which have a higher background activity thanthe MmRXR/EcR switches in the absence of ligand

Finally, the GAL4EcR/VP16RXR switch (Switch 1.1) was more sensitive tonon-steroid ligands than to the steroid ligands (see Tables 5 and 6). Inparticular, steroid ligands initiated transactivation at concentrationsof 50 μM, whereas the non-steroid ligands initiated transactivation atless than 1 μM (submicromolar) concentration.

Example 2

This Example describes Applicants' further analysis of truncated EcR andRXR polypeptides in the improved EcP-based inducible gene expressionsystem of the invention. To identify the best combination and length oftwo receptors that give a switch with a) maximum induction in thepresence of ligand; b) minimum background in the absence of ligand; c)highly sensitive to ligand concentration; and d) minimum cross-talkamong ligands and receptors, Applicants made and analyzed severaltruncation mutations of the CfEcR and MmRXR receptor polypeptides inNIH3T3 cells.

Briefly, polynucleotides encoding EcR or RXR receptors were truncated atthe junctions of A/B, C, D, E and F domains and fused to either a GAL4DNA binding domain encoding polynucleotide (SEQ ID NO: 41) for CfEcR, ora VP16 activation domain encoding polynucleotide (SEQ ID NO: 45) forMmRXR as described in Example 1. The resulting receptortruncation/fusion polypeptides were assayed in NIH3T3 cells. PlasmidpFRLUC (Stratagene) encoding a luciferase polypeptide was used as areporter gene construct and pTKRL (Promega) encoding a Renillaluciferase polypeptide under the control of the constitutive TK promoterwas used to normalize the transfections as described above. The analysiswas performed in triplicates and mean luciferase counts were determinedas described above.

Gene Expression Cassettes Encoding Truncated Ecdysone ReceptorPolypeptides

Gene expression cassettes comprising polynucleotides encoding eitherfull length or truncated CfEcR polypeptides fused to a GALA. DNA bindingdomain (SEQ ID NO: 41): GAL4CfEcRA/BCDEF (full length CfEcRA/BCDEF; SEQID NO: 49), GAL4CfEcRCDEF (CfEcRCDEF; SEQ ID NO: 1), GAL4CfEcR1/2CDEF(CfEcR1J2CDEF; SEQ ID NO: 2), GAL4CfEcRDEF (CfEcRDEF; SEQ ID NO: 3),GAL4CfEcREF (CfEcREF; SEQ ID NO: 4), and GAL4CfEcRDE (CfEcRDE; SEQ IDNO: 5) were transfected into NIH3T3 cells along with VP16MmRXRDEF(constructed as in Example 1.1; FIG. 11) or VP16MmRXREF [constructed asin Example 1.1 except that MmRXRDEF was replaced with MmRXREF (SEQ IDNO: 23); FIG. 12], and pFRLUc and pTKRL plasmid DNAs. The transfectedcells were grown in the presence 0, 1, 5 or 25 uM ofN-(2-ethyl-3-methoxybenzoyl)-N′-(3,5-dimethylbenzoyl)-N′-tert-butylhydrazineor PonA for 48 hr. The cells were harvested, lysed and luciferasereporter activity was measured in the cell lysates. Total fly luciferaserelative light units are presented. The number on the top of each bar isthe maximum fold induction for that treatment.

Applicants' results show that the EF domain of MmRXR is sufficient andperforms better than DEF domains of this receptor (see FIGS. 11 and 12).Applicants have also shown that, in general, EcR/RXR receptorcombinations are insensitive to PonA (see FIGS. 11 and 12). As shown inthe FIGS. 11 and 12, the GAL4CfEcRCDEF hybrid polypeptide (SEQ ID NO: 7)performed better than any other CfEcR hybrid polypeptide.

Gene Expression Cassettes Encoding Truncated Retinoid X ReceptorPolypeptides

Gene expression cassettes comprising polynucleotides encoding eitherfull length or truncated MmRXR polypeptides fused to a VP16transactivation domain (SEQ ID NO: 45): VP16MmRXRA/BCDEF (full lengthMmRXRA/BCDEF; SEQ ID NO: 53), VP16MmRXRCDEF (MmRXRCDEF; SEQ ID NO: 21),VP16MmRXRDEF (MmRXRDEF; SEQ ID NO: 22). VP16MmRXREF (MmRXREF, SEQ ID NO:23), VP16MmRXRBam-EF (“MmRXRBam-EF” or “MmRXR-truncatedEF”; SEQ ID NO:24), and VP16MmRXRAF2del (“MmRXRAF2del” or “MmRXR-E”; SEQ ID NO: 25)constructs were transfected into NIH3T3 cells along with GAl4CfEcRCDEF(constructed as in Example 1.1; FIG. 13) or GAL4CfEcRDEF [constructed asin Example 1.1 except CfEcRCDEF was replaced with CfEcRDEF (SEQ ID NO:3); FIG. 14], pFRLUc and pTKRL plasmid DNAs as described above. Thetransfected cells were grown in the presence 0, 1, 5 and 25 uM ofN-(2-ethyl-3-methoxybenzoyl)-N′-(3,5-dimethylbenzoyl)-N′-tert-butylhydrazineor PonA for 48 hr. The cells were harvested and lysed and reporteractivity was measured in the cell lysate. Total fly luciferase relativelight units are presented. The number on top of each bar is the maximumfold induction in that treatment.

Of all the truncations of MmRXR tested, Applicants' results show thatthe MmRXREF receptor was the best partner for CfEcR (FIGS. 13 and 14).CfEcRCDEF showed better induction than CfEcRDEF using MmRXREF. DeletingAF2 (abbreviated “EF-AF2del”) or helices 1-3 of the E domain(abbreviated “EF-Barndel”) resulted in an RXR receptor that reduced geneinduction and ligand sensitivity when partnered with either CfEcRCDEF(FIG. 13) or CfEcRDEF (FIG. 14) in NIH3T3 cells. In general, theCfEcR/RXR-based switch was much more sensitive to the non-steroidN-(2-ethyl-3-methoxybenzoyl)-N′-(3,5-dimethylbenzoyl)-N′-tert-butylhydrazinethan to the steroid PonA.

Example 3

This Example describes Applicants' further analysis of gene expressioncassettes encoding truncated EcR or RXR receptor polypeptides thataffect either ligand binding activity or ligand sensitivity, or both.Briefly, six different combinations of chimeric receptor pairs,constructed as described in Examples 1 and 2, were further analyzed in asingle experiment in NIH3T3 cells. These six receptor pair combinationsand their corresponding sample numbers are depicted in Table 7.

TABLE 7 CfEcR + MmRXR Truncation Receptor Combinations in NIH3T3 CellsFIG. 15 EcR Polypeptide RXR Polypeptide X-Axis Sample No. ConstructConstruct Samples 1 and 2 GAL4CfEcRCDEF VP16RXRA/BCDEF (Full length)Samples 3 and 4 GAL4CfEcRCDEF VP16RXRDEF Samples 5 and 6 GAL4CfEcRCDEFVP16RXREF Samples 7 and 8 GAL4CfEcRDEF VP16RXRA/BCDEF (Full length)Samples 9 and 10 GAL4CfEcRDEF VP16RXRDEF Samples 11 and 12 GAL4CfEcRDEFVP16RXREF

The above receptor construct pairs, along with the reporter plasmidpFRLuc were transfected into NIH3T3 cells as described above. The sixCfEcR truncation receptor combinations were duplicated into two groupsand treated with either steroid (odd numbers on x-axis of FIG. 15) ornon-steroid (even numbers on x-axis of FIG. 15). In particular, thecells were grown in media containing 0, 1, 5 or 25 uM PonA (steroid) orN-(2-ethyl-3-methoxybenzoyl)-N′-(3,5-dimethylbenzoyl)-N′-tert-butylhydrazine(non-steroid) ligand. The reporter gene activity was measured and totalRLU are shown. The number on top of each bar is the maximum foldinduction for that treatment and is the mean of three replicates.

As shown in FIG. 15, the CfEcRCDEF/MmRXREF receptor combinations werethe best switch pairs both in terms of total RLU and fold induction(compare columns 1-6 to columns 7-12). This confirms Applicants' earlierfindings as described in Example 2 (FIGS. 11-14). The same geneexpression cassettes encoding the truncated EcR and RXR polypeptideswere also assayed in a human lung carcinoma cell line A549 (ATCC) andsimilar results were observed (data not shown).

1-71. (canceled)
 72. A non-human organism comprising a polynucleotidesequence encoding a gene switch comprising: (a) a first gene expressioncassette comprising a polynucleotide sequence that encodes a firstpolypeptide comprising an ecdysone receptor ligand binding domain; and(b) a second gene expression cassette comprising a polynucleotidesequence that encodes a second polypeptide comprising a nuclear receptorligand binding domain, wherein one of the first gene expression cassetteor the second gene expression cassette comprises a DNA-binding domainthat recognizes a response element associated with a gene of interest,wherein the first gene expression cassette or the second gene expressioncassette that does not comprise the DNA-binding domain comprises atransactivation domain, wherein the ligand binding domain in the firstpolypeptide and the ligand binding domain in the second polypeptide aredifferent and dimerize, wherein at least one of the first polypeptideand the second polypeptide does not contain the A and B domains of thecorresponding ecdysone receptor or nuclear receptor ligand bindingdomain, wherein the gene switch is more sensitive to a diacylhydrazineligand than to a steroid ligand, and wherein the gene that is expressedis a component of a chimeric gene comprising: (i) a response element towhich the DNA-binding domain binds; (ii) a promoter that is activated bythe transactivation domain; and (iii) the gene that is expressed. 73.The non-human organism of claim 72, wherein the gene switch furthercomprises: (c) a third gene expression cassette comprising (i) aresponse element to which the DNA-binding domain of the firstpolypeptide binds; (ii) a promoter that is activated by thetransactivation domain of the second polypeptide; and (iii) the genethat is expressed.
 74. The non-human organism of claim 73, wherein thediacylhydrazine ligand is a compound of the formula:

wherein: E is a (C₄-C₆)alkyl containing a tertiary carbon or acyano(C₃-C₅)alkyl containing a tertiary carbon; R¹ is H, Me, Et, i-Pr,F, formyl, CF₃, CHF₂, CHCl₂, CH₂F, CH₂Cl, CH₂OH, CH₂OMe, CH₂CN, CN,C≡CH, 1-propynyl, 2-propynyl, vinyl, OH, OMe, OEt, cyclopropyl, CF₂CF₃,CH═CHCN, allyl, azido, SCN, or SCHF₂; R² is H, Me, Et, n-Pr, i-Pr,formyl, CF₃, CHF₂, CHCl₂, CH₂F, CH₂Cl, CH₂OH, CH₂OMe, CH₂CN, CN, C≡CH,1-propynyl, 2-propynyl, vinyl, Ac, F, Cl, OH, OMe, OEt, O-n-Pr, OAc,NMe₂, NEt₂, SMe, SEt, SOCF₃, OCF₂CF₂H, COEt, cyclopropyl, CF₂CF₃,CH═CHCN, allyl, azido, OCF₃, OCHF₂, O-i-Pr, SCN, SCHF₂, SOMe, NH—CN, orjoined with R³ and the phenyl carbons to which R² and R³ are attached toform an ethylenedioxy, a dihydrofuryl ring with the oxygen adjacent to aphenyl carbon, or a dihydropyryl ring with the oxygen adjacent to aphenyl carbon; R³ is H, Et, or joined with R² and the phenyl carbons towhich R² and R³ are attached to form an ethylenedioxy, a dihydrofurylring with the oxygen adjacent to a phenyl carbon, or a dihydropyryl ringwith the oxygen adjacent to a phenyl carbon; R⁴, R⁵, and R⁶ areindependently H, Me, Et, F, Cl, Br, formyl, CF₃, CHF₂, CHCl₂, CH₂F,CH₂Cl, CH₂OH, CN, 1-propynyl, 2-propynyl, vinyl, OMe, OEt, SMe, or SEt.75. The non-human organism of claim 72, wherein the ligand bindingdomain of the first polypeptide is encoded by a polynucleotidecomprising a nucleic acid sequence selected from the group consisting ofSEQ ID NO:1, SEQ ID NO:2, SEQ ID N0:3, SEQ ID N0:4, SEQ ID NO:5, SEQ IDNO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10.
 76. Thenon-human organism of claim 72, wherein the ligand binding domain of thefirst polypeptide comprises an amino acid sequence selected from thegroup consisting of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ IDNO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ IDNO:19, and SEQ ID NO:20.
 77. The non-human organism of claim 72, whereinthe ligand binding domain of the second polypeptide is encoded by apolynucleotide comprising a nucleic acid sequence selected from thegroup consisting of SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ IDNO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ IDNO:29, and SEQ ID NO:30.
 78. The non-human organism of claim 72, whereinthe ligand binding domain of the second polypeptide comprises an aminoacid sequence selected from the group consisting of SEQ ID NO:31, SEQ IDNO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ IDNO37, SEQ ID NO:38, SEQ ID NO:39, and SEQ ID NO:40.
 79. The non-humanorganism of claim 72, wherein said polynucleotide sequence is containedin a vector.
 80. The non-human organism of claim 79, wherein said vectoris a plasmid.
 81. The non-human organism of claim 79, wherein saidvector is an expression vector.
 82. The non-human organism of claim 79,wherein said vector is a viral vector.
 83. The non-human organism ofclaim 82, wherein said viral vector is an adenovirus vector.
 84. Thenon-human organism of claim 72, wherein the ecdysone receptor ligandbinding domain is selected from the group consisting of a Lepidopteranecdysone receptor ligand binding domain, a Dipteran ecdysone receptorligand binding domain, an Arthropod ecdysone receptor ligand bindingdomain, a Homopteran ecdysone receptor ligand binding domain, a sprucebudworm Choristoneura fumiferana ecdysone receptor ligand bindingdomain, a Tenebrio molitor ecdysone receptor ligand binding domain, aManduca sexta ecdysone receptor ligand binding domain, a Heliothiesvirescens ecdysone receptor ligand binding domain, a silk moth Bombyxmori ecdysone receptor ligand binding domain, a fruit fly Drosophilamelanogaster ecdysone receptor ligand binding domain, a mosquito Aedesaegypti ecdysone receptor ligand binding domain, a blowfly Luciliacapitata ecdysone receptor ligand binding domain, a Mediterranean fruitfly Ceratitis capitata ecdysone receptor ligand binding domain, a locustLocusta migratoria ecdysone receptor ligand binding domain, an aphidMyzus persicae ecdysone receptor ligand binding domain, a fiddler crabUca pugilator ecdysone receptor ligand binding domain, and an ixodidtick Amblyomma americanum ecdysone receptor ligand binding domain. 85.The non-human organism of claim 84, wherein the ecdysone receptor ligandbinding domain is a Choristoneura fumiferana ecdysone receptor ligandbinding domain.
 86. The non-human organism of claim 72, wherein theexpression of the gene switch is tissue-specific expression.
 87. Thenon-human organism of claim 72, wherein said first polypeptide does notcontain the A and B domains of the ecdysone receptor.
 88. The non-humanorganism of claim 72, wherein said second polypeptide does not containthe A and B domains of the nuclear receptor.
 89. The non-human organismof claim 72, wherein said first polypeptide does not contain the A and Bdomains said ecdysone receptor, and wherein said second polypeptide doesnot contain the A and B domains of the nuclear receptor.
 90. Thenon-human organism of claim 72, wherein said gene switch modulationsystem is more sensitive to a diacylhydrazine ligand than to a steroidligand when expressed in a mammalian cell.
 91. The non-human organism ofclaim 72, wherein said DNA binding domain is selected from the groupconsisting of a GAL4 DNA binding domain, a LexA DNA binding domain, atranscription factor DNA binding domain, a steroid/thyroid hormonenuclear receptor superfamily member DNA binding domain and a bacterialLacZ DNA binding domain.
 92. The non-human organism of claim 72, whereinsaid transactivation domain is selected from the group consisting of asteroid/thyroid hormone nuclear receptor transactivation domain, apolyglutamine transactivation domain, a basic or acidic amino acidtransactivation domain, a VP16 transactivation domain, a GAL4transactivation domain, an NF-κB transactivation domain and a BP64transactivation domain.
 93. The non-human organism of claim 72, whereinsaid nuclear receptor ligand binding domain of the second polypeptide isa retinoic X receptor ligand binding domain.
 94. The non-human organismof claim 93, wherein said retinoic X receptor ligand binding domain ofthe second polypeptide is selected from the group consisting of a mouseMus musculus retinoic X receptor ligand binding domain, a human Homosapiens retinoic X receptor ligand binding domain.
 95. The non-humanorganism of claim 93, wherein said retinoic X receptor ligand bindingdomain of the second polypeptide is selected from the group consistingof an RXRα ligand binding domain, an RXRβ ligand binding domain and anRXRγ ligand binding domain.
 96. The non-human organism of claim 72,wherein said organism is selected from the group consisting of abacterial cell, a fungal cell, a plant cell, an animal cell, and amammalian cell.
 97. The non-human organism claim 96, wherein said fungalcell is selected from the group consisting of an Aspergillus cell, aTrichoderma cell, a Saccharomyces cell, a Pichia cell, a Candida cell,and a Hansenula cell.
 98. The non-human organism of claim 96, whereinsaid bacterial cell is selected from the group consisting of aSynechocystis cell, a Synechococcus cell, a Salmonella cell, a Bacilluscell, an Acinetobacter cell, a Rhodococcus cell, a Streptomyces cell, anEscherichia cell, a Pseudomonas cell, a Methylomonas cell, aMethylobacter cell, an Alcaligenes cell, a Synechocystis cell, anAnabaena cell, a Thiobacillus cell, a Methanobacterium cell and aKlebsiella cell.
 99. The non-human organism of claim 72, wherein saidorganism is a plant cell.
 100. The non-human organism of claim 99,wherein said plant cell is selected from the group consisting of anapple cell, an Arabidopsis cell, a bajra cell, a banana cell, a barleycell, a bean cell, a beet cell, a blackgram cell, a chickpea cell, achili cell, a cucumber cell, an eggplant cell, a favabean cell, a maizecell, a melon cell, a millet cell, a mungbean cell, an oat cell, an okracell, a Panicum cell, a papaya cell, a peanut cell, a pea cell, a peppercell, a pigeonpea cell, a pineapple cell, a Phaseolus cell, a potatocell, a pumpkin cell, a rice cell, a sorghum cell, a soybean cell, asquash cell, a sugarcane cell, a sugarbeet cell, a sunflower cell, asweet potato cell, a tea cell, a tomato cell, a tobacco cell, awatermelon cell, and a wheat cell.
 101. The non-human organism of claim96 wherein said organism is a mammalian cell.
 102. The non-humanorganism of claim 101, wherein said mammalian cell is selected from thegroup consisting of a hamster cell, a mouse cell, a rat cell, a rabbitcell, a cat cell, a dog cell, a bovine cell, a goat cell, a cow cell, apig cell, a horse cell, a sheep cell, a monkey cell, and a chimpanzeecell.
 103. The non-human organism of claim 72, wherein said firstpolypeptide comprises a DNA binding domain and the second polypeptidecomprises a transactivation domain.
 104. The non-human organism of claim72, wherein said first polypeptide comprises a transactivation domainand the second polypeptide comprises a DNA binding domain.